WO2015042246A1 - Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors - Google Patents
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors Download PDFInfo
- Publication number
- WO2015042246A1 WO2015042246A1 PCT/US2014/056277 US2014056277W WO2015042246A1 WO 2015042246 A1 WO2015042246 A1 WO 2015042246A1 US 2014056277 W US2014056277 W US 2014056277W WO 2015042246 A1 WO2015042246 A1 WO 2015042246A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- lag
- seq
- set forth
- chain variable
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 192
- 238000011282 treatment Methods 0.000 claims abstract description 97
- 238000000034 method Methods 0.000 claims abstract description 66
- 230000004044 response Effects 0.000 claims description 57
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 31
- 230000003902 lesion Effects 0.000 claims description 30
- 201000001441 melanoma Diseases 0.000 claims description 29
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 27
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 23
- 241000701806 Human papillomavirus Species 0.000 claims description 12
- 230000009467 reduction Effects 0.000 claims description 11
- 230000036961 partial effect Effects 0.000 claims description 10
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 238000011260 co-administration Methods 0.000 claims description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 208000037844 advanced solid tumor Diseases 0.000 abstract description 9
- 229960003301 nivolumab Drugs 0.000 description 134
- 229940125565 BMS-986016 Drugs 0.000 description 127
- 102000017578 LAG3 Human genes 0.000 description 53
- 101150030213 Lag3 gene Proteins 0.000 description 51
- 239000003814 drug Substances 0.000 description 48
- 238000002560 therapeutic procedure Methods 0.000 description 45
- 229940079593 drug Drugs 0.000 description 44
- 150000001413 amino acids Chemical group 0.000 description 43
- 238000001574 biopsy Methods 0.000 description 43
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 42
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 41
- 230000002411 adverse Effects 0.000 description 35
- 201000011510 cancer Diseases 0.000 description 33
- 210000001744 T-lymphocyte Anatomy 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 29
- 238000009175 antibody therapy Methods 0.000 description 29
- 229940045513 CTLA4 antagonist Drugs 0.000 description 28
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 23
- 208000014829 head and neck neoplasm Diseases 0.000 description 22
- 239000000090 biomarker Substances 0.000 description 19
- 230000001988 toxicity Effects 0.000 description 18
- 231100000419 toxicity Toxicity 0.000 description 18
- 108010074708 B7-H1 Antigen Proteins 0.000 description 17
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 17
- 208000037821 progressive disease Diseases 0.000 description 17
- 201000010536 head and neck cancer Diseases 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 15
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000003285 pharmacodynamic effect Effects 0.000 description 14
- 241000282693 Cercopithecidae Species 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 238000002648 combination therapy Methods 0.000 description 13
- 238000003364 immunohistochemistry Methods 0.000 description 13
- 241000282567 Macaca fascicularis Species 0.000 description 12
- 229960005386 ipilimumab Drugs 0.000 description 12
- 238000002203 pretreatment Methods 0.000 description 12
- 238000009097 single-agent therapy Methods 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000034994 death Effects 0.000 description 11
- 231100000517 death Toxicity 0.000 description 11
- 238000001647 drug administration Methods 0.000 description 11
- 230000005847 immunogenicity Effects 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 10
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 10
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 206010035664 Pneumonia Diseases 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 7
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229940028334 follicle stimulating hormone Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 231100001106 life-threatening toxicity Toxicity 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229950007217 tremelimumab Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000001398 Granzyme Human genes 0.000 description 6
- 108060005986 Granzyme Proteins 0.000 description 6
- 108091054438 MHC class II family Proteins 0.000 description 6
- 206010035742 Pneumonitis Diseases 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000001364 causal effect Effects 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000002489 hematologic effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000007901 in situ hybridization Methods 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 102000043131 MHC class II family Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 229940000406 drug candidate Drugs 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000002547 new drug Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 4
- 206010072268 Drug-induced liver injury Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010059282 Metastases to central nervous system Diseases 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 208000025997 central nervous system neoplasm Diseases 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 238000011284 combination treatment Methods 0.000 description 4
- 108091008034 costimulatory receptors Proteins 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 231100000041 toxicology testing Toxicity 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 206010001367 Adrenal insufficiency Diseases 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010020850 Hyperthyroidism Diseases 0.000 description 3
- -1 IL-12p70 Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 101001137986 Mus musculus Lymphocyte activation gene 3 protein Proteins 0.000 description 3
- 102000004503 Perforin Human genes 0.000 description 3
- 108010056995 Perforin Proteins 0.000 description 3
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 210000002987 choroid plexus Anatomy 0.000 description 3
- 230000009850 completed effect Effects 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002059 diagnostic imaging Methods 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 238000002565 electrocardiography Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002657 hormone replacement therapy Methods 0.000 description 3
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000000370 laser capture micro-dissection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 229930192851 perforin Natural products 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002250 progressing effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 238000011272 standard treatment Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000032862 Clinical Deterioration Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 208000002633 Febrile Neutropenia Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
- 102100023123 Mucin-16 Human genes 0.000 description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010043275 Teratogenicity Diseases 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003890 endocrine cell Anatomy 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000007387 excisional biopsy Methods 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 238000009802 hysterectomy Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 102000027596 immune receptors Human genes 0.000 description 2
- 108091008915 immune receptors Proteins 0.000 description 2
- 238000013394 immunophenotyping Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009247 menarche Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 208000019465 refractory cytopenia of childhood Diseases 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 231100000378 teratogenic Toxicity 0.000 description 2
- 230000003390 teratogenic effect Effects 0.000 description 2
- 231100000211 teratogenicity Toxicity 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000009258 tissue cross reactivity Effects 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005006 Bladder cancer stage 0, with cancer in situ Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000736355 Euthyroides Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010050551 Lupus-like syndrome Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 208000032818 Microsatellite Instability Diseases 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029306 Neurological signs and symptoms Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000288935 Platyrrhini Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000014267 Thyroid peroxidases Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010045169 Tumour flare Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 231100001015 blood dyscrasias Toxicity 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000009198 gamma knife radiosurgery Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000002602 induced regulatory T cell Anatomy 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000002501 natural regulatory T cell Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000011375 palliative radiation therapy Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 231100001271 preclinical toxicology Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000007047 pulmonary toxicity Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000019908 regulation of T cell activation Effects 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000009528 vital sign measurement Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- Lymphocyte activation gene-3 (LAG-3; CD223) is a type I transmembrane protein that is expressed on the cell surface of activated CD4 + and CD8 + T cells and subsets of NK and dendritic cells (Triebel F, et al., J. Exp. Med. 1990; 171: 1393- 1405; Workman CJ, et al, J. Immunol. 2009; 182(4): 1885-91).
- LAG-3 is closely related to CD4, which is a co-receptor for T helper cell activation. Both molecules have 4 extracellular Ig-like domains and require binding to their ligand, major
- MHC histocompatibility complex
- LAG-3 is only expressed on the cell surface of activated T cells and its cleavage from the cell surface terminates LAG-3 signaling. LAG-3 can also be found as a soluble protein but it does not bind to MHC class II and its function is unknown.
- Treg regulatory T cell activity and in negatively regulating T cell activation and proliferation (Workman CJ, et al, J. Immunol. 2005; 174:688-695). Both natural and induced Treg express increased LAG-3, which is required for their maximal
- LAG-3 maintained tolerance to self and tumor antigens via direct effects on CD8 + T cells in 2 murine models (Grosso JF, et al., J. Clin. Invest. 2007; 117:3383-3392).
- Exhausted T cells are characterized by the expression of T cell negative regulatory receptors, predominantly CTLA-4, PD-1, and LAG-3, whose action is to limit the cell's ability to proliferate, produce cytokines, and kill target cells and/or to increase Treg activity.
- T cell negative regulatory receptors predominantly CTLA-4, PD-1, and LAG-3
- PD-1 Programmed Cell Death 1
- PD-1 is a cell surface signaling receptor that plays a critical role in the regulation of T cell activation and tolerance (Keir ME, et al., Annu Rev Immunol 2008; 26:677-704). It is a type I transmembrane protein and together with BTLA, CTLA-4, ICOS and CD28, comprise the CD28 family of T cell co-stimulatory receptors.
- PD-1 is primarily expressed on activated T cells, B cells, and myeloid cells (Dong H, et al., Nat Med. 1999; 5: 1365-1369). It is also expressed on natural killer (NK) cells (Terme M, et al., Cancer Res 2011; 71:5393-5399).
- PD-1 One important role of PD-1 is to limit the activity of T cells in peripheral tissues at the time of an inflammatory response to infection, thus limiting the development of autoimmunity (Pardoll DM., Nat Rev Cancer 2012; 12:252-264).
- lymphocytes, and its ligands are up-regulated on the cell surface of many different tumors (Dong H, et al., Nat Med 2002; 8:793-800).
- Multiple murine cancer models have demonstrated that binding of ligand to PD-1 results in immune evasion.
- blockade of this interaction results in anti-tumor activity (Topalian SL, et al. NEJM 2012; 366(26):2443-2454; Hamid O, et al, NEJM 2013; 369: 134-144).
- tumors e.g., advanced refractory solid tumors.
- solid tumors e.g., advanced refractory solid tumors
- administering to the patient a combination of an anti-LAG-3 antibody and an anti-PD- 1 antibody, wherein the combination is administered (or is for administration) according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule).
- a particular clinical dosage regimen i.e., at a particular dose amount and according to a specific dosing schedule.
- the human patient suffers from melanoma, non- small cell lung cancer (NSCLC), virally-related cancer, head and neck cancer (HNC) or gastric adenocarcinoma.
- NSCLC non- small cell lung cancer
- HNC head and neck cancer
- gastric adenocarcinoma gastric adenocarcinoma
- An exemplary anti-LAG-3 antibody is BMS-986016 comprising heavy and light chains comprising the sequences shown in SEQ ID NOs: 1 and 2, respectively, or antigen binding fragments and variants thereof.
- the antibody comprises the heavy and light chain complementarity determining regions (CDRs) or variable regions (VRs) of BMS-986016.
- the antibody comprises CDRl, CDR2, and CDR3 domains of the heavy chain variable (VH) region of BMS- 986016 having the sequence shown in SEQ ID NO:3, and CDRl, CDR2 and CDR3 domains of the light chain variable (VL) region of BMS-986016 having the sequence shown in SEQ ID NO:5.
- the antibody comprises CDRl, CDR2 and CDR3 heavy chain sequences set forth in SEQ ID NOs:7, 8, and 9, respectively, and CDRl, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs: 10, 11, and 12, respectively.
- the antibody has VH and/or VL regions comprising the amino acid sequences set forth in SEQ ID NO:3 and/or SEQ ID NO:5, respectively.
- the antibody comprises the VH and/or VL regions encoded by the nucleic acid sequences set forth in SEQ ID NO:4 and/or SEQ ID NO:6, respectively.
- the antibody competes for binding with, and/or binds to the same epitope on LAG-3 as, the above-mentioned antibodies.
- the antibody has at least about 90% variable region amino acid sequence identity with the above-mentioned antibodies (e.g., at least about 90%, 95% or 99% variable region identity with SEQ ID NO:3 or SEQ ID NO:5).
- An exemplary anti-PD- 1 antibody is Nivolumab (also referred to as "5C4" in WO 2006/121168; and known as BMS-936558, MDX- 1106 and ONO-4538) comprising heavy and light chains comprising the sequences shown in SEQ ID NOs: 17 and 18, respectively, or antigen binding fragments and variants thereof.
- the antibody comprises the heavy and light chain CDRs or VRs of BMS-936558.
- the antibody comprises CDRl, CDR2, and CDR3 domains of the VH region of BMS-936558 having the sequence shown in SEQ ID NO: 19, and CDRl, CDR2 and CDR3 domains of the VL region of BMS-936558 having the sequence shown in SEQ ID NO:21.
- the antibody comprises heavy chain CDRl, CDR2 and CDR3 domains comprising the sequences set forth in SEQ ID NOs:23, 24, and 25, respectively, and light chain CDRl, CDR2 and CDR3 domains comprising the sequences set forth in SEQ ID NOs: 26, 27, and 28, respectively.
- the antibody comprises VH and/or VL regions comprising the amino acid sequences set forth in SEQ ID NO: 19 and/or SEQ ID NO:21, respectively.
- the antibody comprises the heavy chain variable (VH) and/or light chain variable (VL) regions encoded by the nucleic acid sequences set forth in SEQ ID NO:20 and/or SEQ ID NO:22, respectively.
- the antibody competes for binding with, and/or binds to the same epitope on PD- 1 as, the above- mentioned antibodies.
- the antibody has at least about 90% variable region amino acid sequence identity with the above-mentioned antibodies (e.g., at least about 90%, 95% or 99% variable region identity with SEQ ID NO: 19 or SEQ ID NO:21).
- methods of treating solid tumors e.g., advanced refractory solid tumors
- the methods comprising administering to the patient, an effective amount of each of:
- an anti-LAG-3 antibody comprising CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the
- an anti-PD- 1 antibody comprising CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO: 19, and
- the method comprises at least one administration cycle, wherein the cycle is a period of eight weeks, wherein for each of the at least one cycles, four doses of the anti-LAG-3 antibody are administered at a dose of 3, 20, 80, or 240 mg and four doses of the anti-PD- 1 antibody are administered at a dose of 80 or 240 mg.
- four doses of the anti-LAG-3 antibody are administered at a dose of about 0.03, 0.25, 1, or 3 mg/kg body weight and four doses of the anti-PD- 1 antibody are administered at a dose of 1 or 3 mg/kg body weight.
- the anti-LAG-3 antibody and anti-PD- 1 antibody are administered at the following doses:
- the anti-LAG-3 antibody and anti-PD-1 antibody are administered at the following doses:
- the dose of the anti-LAG-3 and/or anti-PD- 1 antibody is calculated per mg/kg body weight.
- the dose of the anti-LAG- 3 and/or anti-PD-1 antibody is a flat-fixed dose.
- an intermediate dose of LAG-3 and/or PD- 1 is used.
- LAG-3 could be administered at 0.4 mg/kg and PD-1 could be administered at 90 mg/kg.
- dosage regimens are adjusted to provide the optimum desired response (e.g. , an effective response).
- the anti-PD- 1 antibody is administered on Days 1, 15, 29, and 43 of each cycle. In another embodiment, the anti-LAG-3 antibody is administered on Days 1, 15, 29, and 43 of each cycle. In another embodiment, the anti-PD- 1 antibody is administered prior to administration of the anti-LAG-3 antibody. In another embodiment, the anti-PD-1 antibody is administered after administration of the anti- LAG-3 antibody. In another embodiment, the treatment consists of up to 12 cycles.
- the anti-PD-1 antibody and anti-LAG-3 antibody are administered as a first ("front") line of treatment (e.g., the initial or first treatment).
- the anti-PD- 1 antibody and anti-LAG-3 antibody are administered as a first ("front") line of treatment (e.g., the initial or first treatment).
- the anti-LAG-3 and anti-PD-1 antibodies can be administered to a subject by any suitable means.
- the antibodies are formulated for
- the antibodies are administered simultaneously (e.g., formulated together in a single formulation or concurrently as separate formulations). Alternatively, in another embodiment, the antibodies are administered sequentially (e.g., as separate formulations). In another embodiment the anti-LAG-3 antibody is administered within about 30 minutes (e.g., within about 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, or less minutes) prior to administration of the anti-PD- 1 antibody.
- the efficacy of the treatment methods provided herein can be assessed using any suitable means.
- the treatment produces at least one therapeutic effect selected from the group consisting of reduction in size of a tumor, reduction in number of metastatic lesions over time, complete response, partial response, and stable disease.
- kits that include a pharmaceutical composition containing an anti-LAG-3 antibody, such as BMS-986016, and an anti-PD-1 antibody, such as BMS-936558, and a pharmaceutically- acceptable carrier, in a therapeutically effective amount adapted for use in the methods described herein.
- the kit comprises:
- an anti-LAG-3 antibody comprising CDRl, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDRl, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:5, for co-administration with an anti-PD-1 antibody comprising CDRl, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO: 19, and CDRl, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:21, in at least one cycle, wherein for each cycle four doses of the anti-LAG-3 antibody are administered at a dose of 3, 20, 80, or 240 mg and four doses of the anti-PD-1 antibody are administered at a dose of 80 or 240 mg. In another embodiment, four doses of the anti-LAG-3 antibody are administered at a dose of 0.03, 0.25, 1, or 3
- the anti-PD- 1 antibody in any of the aforementioned embodiments is replaced by, or combined with, an anti-PD-Ll or anti-PD-L2 antibody.
- the invention also features methods, compositions and kits for treating tumors in human patients using the above-described clinically effective dosages of an anti-LAG-3 antibody combined with the above-described clinically effective dosages of an anti-PD-1 antibody, wherein the dosage of the PD-1 antibody is replaced with the same dosage of an anti-PD-Ll or anti-PD-L2 antibody.
- Figure 1 shows inhibition of tumor growth in vivo using a combination treatment of an anti-LAG-3 antibody and an anti-PD-1 antibody in a murine tumor model.
- Figures 2A and 2B are schematics illustrating the parts of a phase I clinical trial.
- Figure 3 is a schematic illustrating the Screening, Treatment, Clinical Follow-up, and Survival Follow-up phases of the clinical trial.
- the term "subject” or “patient” is a human cancer patient (e.g., a patient having an advanced solid tumor, such as an advanced refractory solid tumor).
- effective treatment refers to treatment producing a beneficial effect, e.g., amelioration of at least one symptom of a disease or disorder.
- a beneficial effect can take the form of an improvement over baseline, i.e., an improvement over a measurement or observation made prior to initiation of therapy according to the method.
- a beneficial effect can also take the form of arresting, slowing, retarding, or stabilizing of a deleterious progression of a marker of solid tumor.
- Effective treatment may refer to alleviation of at least one symptom of a solid tumor.
- Such effective treatment may, e.g., reduce patient pain, reduce the size and/or number of lesions, may reduce or prevent metastasis of a tumor, and/or may slow tumor growth.
- an effective amount refers to an amount of an agent that provides the desired biological, therapeutic, and/or prophylactic result. That result can be reduction, amelioration, palliation, lessening, delaying, and/or alleviation of one or more of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
- an effective amount comprises an amount sufficient to cause a tumor to shrink and/or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to prevent or delay other unwanted cell proliferation.
- an effective amount is an amount sufficient to delay tumor development.
- an effective amount is an amount sufficient to prevent or delay tumor recurrence.
- An effective amount can be administered in one or more administrations.
- the effective amount of the drug or composition may: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and may stop cancer cell infiltration into peripheral organs; (iv) inhibit (i.e., slow to some extent and may stop tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrence of tumor; and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer.
- an "effective amount" is the amount of anti-LAG-3 antibody and the amount of anti-PD-1 antibody, in combination, clinically proven to affect a significant decrease in cancer or slowing of progression of cancer, such as an advanced solid tumor.
- the terms “fixed dose”, “flat dose” and “flat-fixed dose” are used interchangeably and refer to a dose that is administered to a patient without regard for the weight or body surface area (BSA) of the patient.
- the fixed or flat dose is therefore not provided as a mg/kg dose, but rather as an absolute amount of the agent (e.g., the anti-LAG-3 antibody and/or anti- PD-1 antibody).
- a "body surface area (BSA)-based dose” refers to a dose (e.g., of the anti-LAG-3 antibody and/or anti-PD- 1 antibody) that is adjusted to the body- surface area (BSA) of the individual patient.
- a BSA-based dose may be provided as mg/kg body weight.
- Du Bois formula see Du Bois D, Du Bois EF (Jun 1916) Archives of Internal Medicine 17 (6): 863-71; and Verbraecken, J. et al. (Apr 2006). Metabolism— Clinical and Experimental 55 (4): 515-24).
- Other exemplary BSA formulas include the Mosteller formula
- antibody describes polypeptides comprising at least one antibody- derived antigen binding site ⁇ e.g., VH/VL region or Fv, or CDR).
- Antibodies include known forms of antibodies.
- the antibody can be a human antibody, a humanized antibody, a bispecific antibody, or a chimeric antibody.
- the antibody also can be a Fab, Fab'2, ScFv, SMIP, Affibody®, nanobody, or a domain antibody.
- the antibody also can be of any of the following isotypes: IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgAsec, IgD, and IgE.
- the antibody may be a naturally occurring antibody or may be an antibody that has been altered ⁇ e.g., by mutation, deletion, substitution, conjugation to a non-antibody moiety).
- an antibody may include one or more variant amino acids (compared to a naturally occurring antibody) which changes a property ⁇ e.g., a functional property) of the antibody.
- a property e.g., a functional property
- numerous such alterations are known in the art which affect, e.g., half-life, effector function, and/or immune responses to the antibody in a patient.
- the term antibody also includes artificial polypeptide constructs which comprise at least one antibody- derived antigen binding site.
- LAG-3 refers to Lymphocyte Activation Gene-3.
- LAGS'' includes variants, isoforms, homologs, orthologs and paralogs.
- antibodies specific for a human LAG-3 protein may, in certain cases, cross-react with a LAG-3 protein from a species other than human.
- the antibodies specific for a human LAG-3 protein may be completely specific for the human LAG-3 protein and may not exhibit species or other types of cross-reactivity, or may cross-react with LAG-3 from certain other species, but not all other species ⁇ e.g., cross-react with monkey LAG-3 but not mouse LAG-3).
- human LAG-3 refers to human sequence LAG-3, such as the complete amino acid sequence of human LAG-3 having Genbank Accession No. NP_002277 (SEQ ID NO: 13).
- mouse LAG-3 refers to mouse sequence LAG-3, such as the complete amino acid sequence of mouse LAG-3 having Genbank Accession No. NP_032505.
- LAG-3 is also known in the art as, for example, CD223.
- the human LAG-3 sequence may differ from human LAG-3 of Genbank Accession No. NP_002277 by having, e.g., conserved mutations or mutations in non-conserved regions and the LAG-3 has substantially the same biological function as the human LAG-3 of Genbank
- a biological function of human LAG-3 is having an epitope in the extracellular domain of LAG-3 that is specifically bound by an antibody of the instant disclosure or a biological function of human LAG-3 is binding to MHC Class II molecules.
- monkey LAG-3 is intended to encompass LAG-3 proteins expressed by Old World and New World monkeys, including but not limited to cynomolgus monkey LAG-3 and rhesus monkey LAG-3.
- a representative amino acid sequence for monkey LAG-3 is the rhesus monkey LAG-3 amino acid sequence which is also deposited as Genbank Accession No. XM_001108923.
- Another representative amino acid sequence for monkey LAG-3 is the alternative rhesus monkey sequence of clone pa23-5 as described in US 2011/0150892 Al . This alternative rhesus sequence exhibits a single amino acid difference, at position 419, as compared to the Genbank-deposited sequence.
- a particular human LAG-3 sequence will generally be at least 90% identical in amino acid sequence to human LAG-3 of Genbank Accession No. NP_002277 and contains amino acid residues that identify the amino acid sequence as being human when compared to LAG-3 amino acid sequences of other species (e.g. , murine).
- a human LAG-3 can be at least 95%, or even at least 96%, 97%, 98%, or 99% identical in amino acid sequence to LAG-3 of Genbank Accession No.
- a human LAG-3 sequence will display no more than 10 amino acid differences from the LAG-3 sequence of Genbank Accession No. NP_002277. In certain embodiments, the human LAG-3 can display no more than 5, or even no more than 4, 3, 2, or 1 amino acid difference from the LAG-3 sequence of Genbank Accession No. NP_002277. Percent identity can be determined as described herein.
- the terms “Programmed Death 1,” “Programmed Cell Death 1,” “Protein PD-1,” “PD- 1,” PD1,” “PDCD1,” “hPD-1” and “hPD-I” are used interchangeably, and include variants, isoforms, species homologs of human PD-1, and analogs having at least one common epitope with PD- 1.
- the complete PD- 1 sequence can be found under GenBank Accession No. U64863 (SEQ ID NO:29).
- the protein Programmed Death 1 (PD- 1) is an inhibitory member of the CD28 family of receptors, that also includes CD28, CTLA-4, ICOS and BTLA. PD-1 is expressed on activated B cells, T cells, and myeloid cells (Agata et ah, supra;
- CTLA-4 and BTLA were discovered through screening for differential expression in cytotoxic T lymphocytes and TH1 cells, respectively.
- CD28, ICOS and CTLA-4 all have an unpaired cysteine residue allowing for homodimerization.
- PD-1 is suggested to exist as a monomer, lacking the unpaired cysteine residue characteristic in other CD28 family members.
- the PD-1 gene is a 55 kDa type I transmembrane protein that is part of the Ig gene superfamily (Agata et al. (1996) Int Immunol 8:765-72).
- PD-1 contains a membrane proximal immunoreceptor tyrosine inhibitory motif (ITIM) and a membrane distal tyrosine-based switch motif (ITSM) (Thomas, M.L. (1995) J Exp Med 181: 1953-6; Vivier, E and Daeron, M (1997) Immunol Today 18:286-91).
- ITIM immunoreceptor tyrosine inhibitory motif
- ITSM membrane distal tyrosine-based switch motif
- PD-1 Although structurally similar to CTLA-4, PD-1 lacks the MYPPPY motif that is critical for B7-1 and B7-2 binding.
- Two ligands for PD-1 have been identified, PD- Ll and PD-L2, that have been shown to downregulate T cell activation upon binding to PD-1 (Freeman et al. (2000) J Exp Med 192:1027-34; Latchman et al. (2001) Nat Immunol 2:261-8; Carter et al. (2002) Eur J Immunol 32:634-43). Both PD-L1 and PD-L2 are B7 homologs that bind to PD-1, but do not bind to other CD28 family members.
- PD-L1 is abundant in a variety of human cancers (Dong et al. (2002) Nat. Med. 8:787-9). The interaction between PD-1 and PD-L1 results in a decrease in tumor infiltrating lymphocytes, a decrease in T-cell receptor mediated proliferation, and immune evasion by the cancerous cells (Dong et al. (2003) J. Mol. Med. 81:281- 7; Blank et al. (2005) Cancer Immunol. Immunother. 54:307-314; Konishi et al.
- Immune suppression can be reversed by inhibiting the local interaction of PD-1 with PD-L1, and the effect is additive when the interaction of PD-1 with PD-L2 is blocked as well (Iwai et al. (2002) Proc. Nat' I. Acad. Sci. USA 99: 12293-7; Brown et al. (2003) J. Immunol. 170:1257-66).
- PD- 1 deficient animals develop various autoimmune phenotypes, including autoimmune cardiomyopathy and a lupus-like syndrome with arthritis and nephritis (Nishimura et al. (1999) Immunity 11 : 141-51; Nishimura et al. (2001) Science 291:319-22).
- PD- 1 has been found to play a role in autoimmune encephalomyelitis, systemic lupus erythematosus, graft-versus-host disease (GVHD), type I diabetes, and rheumatoid arthritis (Salama et al. (2003) J Exp Med 198:71-78; Prokunina and
- P-L1 Programmed Death Ligand-1
- PD-L1 cytokine secretion upon binding to PD-1.
- PD-L1 includes human PD-L1 (hPD-Ll), variants, isoforms, and species homologs of hPD-Ll, and 5
- Anti-human-LAG-3 antibodies (or VH/VL domains derived therefrom) suitable for use in the invention can be generated using methods well known in the art.
- art recognized anti-LAG-3 antibodies can be used.
- the anti-human LAG-3 antibody described in US2011/0150892 Al the teachings of which are hereby incorporated by reference, and referred to as monoclonal antibody 25F7 (also known as "25F7" and "LAG3.1) can be used.
- Other art recognized anti-LAG-3 antibodies that can be used include IMP731 described in US 2011/007023, the teachings of which also are hereby incorporated by reference.
- antibodies for binding to LAG-3 also can be used.
- An exemplary anti-LAG-3 antibody is BMS-986016 comprising heavy and light chains comprising the sequences shown in SEQ ID NOs: 1 and 2, respectively, or antigen binding fragments and variants thereof, as described in PCT/US 13/48999, the teachings of which are hereby incorporated by reference.
- the antibody has the heavy and light chain CDRs or variable regions of BMS-986016. Accordingly, in one embodiment, the antibody
- the antibody comprises CDR1, CDR2, and CDR3 domains of the VH region of BMS-986016 having the sequence set forth in SEQ ID NO:3, and CDRl, CDR2 and CDR3 domains of the VL region of BMS-986016 having the sequence set forth in SEQ ID NO:5.
- the antibody comprises CDRl, CDR2 and CDR3 domains comprising the sequences set forth in SEQ ID NOs:7, 8, and 9, respectively, and CDRl, CDR2 and CDR3 domains comprising the sequences set forth in SEQ ID NOs: 10, 11, and 12, respectively.
- the antibody comprises VH and/or VL regions comprising the amino acid sequences set forth in SEQ ID NO:3 and/or SEQ ID NO: 5, respectively.
- the antibody comprises heavy chain variable (VH) and/or light chain variable (VL) regions encoded by the nucleic acid sequences set forth in SEQ ID NO:4 and/or SEQ ID NO:6, respectively.
- the antibody competes for binding with and/or binds to the same epitope on LAG-3 as the above-mentioned antibodies.
- the antibody binds an epitope of human LAG-3 comprising the amino acid sequence PGHPLAPG (SEQ ID NO: 14).
- the antibody binds an epitope of human LAG-3 comprising the amino acid sequence HPAAPSSW (SEQ ID NO: 15) or PAAPSSWG (SEQ ID NO: 16).
- the antibody has at least about 90% variable region amino acid sequence identity with the above-mentioned antibodies (e.g., at least about 90%, 95% or 99% variable region identity with SEQ ID NO:3 or SEQ ID NO:5).
- Anti-human-PD-1 antibodies (or VH and/or VL domains derived therefrom) suitable for use in the invention can be generated using methods well known in the art.
- art recognized anti-PD- 1 antibodies can be used.
- monoclonal antibodies 5C4 (referred to herein as Nivolumab or BMS-936558), 17D8, 2D3, 4H1, 4A11, 7D3, and 5F4, described in WO 2006/121168, the teachings of which are hereby incorporated by reference, can be used.
- Other known PD-1 antibodies include Lambrolizumab (MK-3475) described in WO 2008/156712, and AMP-514 described in WO 2012/145493, the teachings of which are hereby incorporated by reference.
- PD-1 antibodies and other PD- 1 inhibitors include those described in WO 2009/014708, WO 03/099196, WO 2009/114335 and WO 2011/161699, the teachings of which are hereby incorporated by reference. Antibodies that compete with any of these art-recognized antibodies or inhibitors for binding to PD- 1 also can be used.
- An exemplary anti-PD- 1 antibody is BMS-936558 comprising heavy and light chains comprising the sequences shown in SEQ ID NOs: 17 and 18, respectively, or antigen binding fragments and variants thereof.
- the antibody has heavy and light chain CDRs or variable regions of BMS-936558. Accordingly, in one embodiment, the antibody comprises CDR1, CDR2, and CDR3 domains of the VH of BMS-936558 having the sequence set forth in SEQ ID NO: 19, and CDR1, CDR2 and CDR3 domains of the VL of BMS-936558 having the sequence set forth in SEQ ID NO:21. In another embodiment, the antibody comprises CDR1, CDR2 and CDR3 domains comprising the sequences set forth in SEQ ID NOs:23, 24, and 25, respectively, and CDR1, CDR2 and CDR3 domains comprising the sequences set forth in SEQ ID NOs:26, 27, and 28, respectively.
- the antibody comprises VH and/or VL regions comprising the amino acid sequences set forth in SEQ ID NO: 19 and/or SEQ ID NO: 21, respectively.
- the antibody comprises heavy chain variable (VH) and/or light chain variable (VL) regions encoded by the nucleic acid sequences set forth in SEQ ID NO:20 and/or SEQ ID NO:22, respectively.
- the antibody competes for binding with and/or binds to the same epitope on PD- 1 as the above-mentioned antibodies.
- the antibody has at least about 90% variable region amino acid sequence identity with the above- mentioned antibodies (e.g., at least about 90%, 95% or 99% variable region identity with SEQ ID NO: 19 or SEQ ID NO:21). lie.
- Anti-PD-Ll Antibodies e.g., at least about 90%, 95% or 99% variable region identity with SEQ ID NO: 19 or SEQ ID NO:21.
- Anti-human-PD-Ll antibodies (or VH and/or VL domains derived therefrom) suitable for use in the invention can be generated using methods well known in the art.
- art recognized anti-PD-Ll antibodies can be used.
- human anti-PD-Ll antibodies disclosed in U.S. Patent No 7,943,743, the contents of which are hereby incorporated by reference can be used.
- Such anti-PD-Ll antibodies include 3G10, 12A4 (also referred to as BMS-936559), 10A5, 5F8, 10H10, IB 12, 7H1, 11E6, 12B7, and 13G4.
- Other art recognized anti-PD-Ll antibodies which can be used include those described in, for example, U.S. Patent Nos.
- compositions suitable for administration to human patients are typically formulated for parenteral administration, e.g., in a liquid carrier, or suitable for reconstitution into liquid solution or suspension for intravenous administration.
- compositions typically comprise a pharmaceutically acceptable carrier.
- pharmaceutically acceptable means approved by a government regulatory agency or listed in the U.S. Pharmacopeia or another generally recognized pharmacopeia for use in animals, particularly in humans.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered.
- Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, glycerol polyethylene glycol ricinoleate, and the like.
- Liquid compositions for parenteral administration can be formulated for administration by injection or continuous infusion. Routes of administration by injection or infusion include intravenous, intraperitoneal, intramuscular, intrathecal and subcutaneous. In one embodiment, the anti-LAG-3 and/or anti-PD- 1 antibodies are administered
- intravenously e.g., in separate formulations or together (in the same formulation or in separate formulations)).
- cancers that may be treated using the methods of the invention, include liver cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, breast cancer, lung cancer, cutaneous or intraocular malignant melanoma, renal cancer, uterine cancer, ovarian cancer, colorectal cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular 20 cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, s
- the human patient suffers from non-small cell lung cancer (NSCLC) or a virally-related cancer (e.g., a human papilloma virus (HPV)-related tumor) or gastric adenocarcinoma.
- NSCLC non-small cell lung cancer
- HPV human papilloma virus
- HPV-related tumor is HPV+ head and neck cancer (HNC).
- HNC head and neck cancer
- the gastric adenocarcinoma is associated with Epstein-Barr virus (EBV) infection.
- EBV Epstein-Barr virus
- Patients can be tested or selected for one or more of the above described clinical attributes prior to, during or after treatment.
- Combination Therapy involves administration of an anti- LAG-3 antibody and another antibody that blocks an inhibitory immune receptor (e.g., a receptor, which upon binding to its natural ligand, inhibits/neutralizes activity, such as cytotoxic activity), particularly an anti-PD-1 antibody, to treat subjects having solid tumors (e.g., advanced refractory solid tumors).
- an inhibitory immune receptor e.g., a receptor, which upon binding to its natural ligand, inhibits/neutralizes activity, such as cytotoxic activity
- an anti-PD-1 antibody e.g., advanced refractory solid tumors.
- the invention provides an anti-LAG-3 antibody and an anti-PD- 1 antibody in combination according to a defined clinical dosage regimen, to treat subjects having a solid tumor (e.g., an advanced refractory solid tumor).
- a solid tumor e.g., an advanced refractory solid tumor.
- the anti-LAG-3 antibody is BMS-986016.
- the anti-PD-1 antibody is BMS-936558.
- dosage regimens are adjusted to provide the optimum desired response (e.g. , an effective response).
- adjunctive or combined administration includes simultaneous administration of the compounds in the same or different dosage form, or separate administration of the compounds (e.g., sequential administration).
- the anti-LAG-3 and anti-PD- 1 antibodies can be
- the anti-LAG-3 and anti-PD-1 antibodies can be formulated for separate administration and are administered concurrently or sequentially (e.g., one antibody is administered within about 30 minutes prior to administration of the second antibody).
- the anti-PDl antibody can be administered first followed by (e.g., immediately followed by) the administration of the anti-LAG-3 antibody, or vice versa.
- the anti-PD- 1 antibody is administered prior to administration of the anti-LAG-3 antibody.
- the anti-PD- 1 antibody is administered after administration of the anti-LAG-3 antibody.
- the anti-LAG-3 antibody and anti-PD-1 antibody are administered concurrently. Such concurrent or sequential administration preferably results in both antibodies being simultaneously present in treated patients.
- Suitable treatment protocols for treating a solid tumor in a human patient include, for example, administering to the patient an effective amount of each of:
- an anti-LAG-3 antibody comprising CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:5,
- an anti-PD- 1 antibody comprising CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO: 19, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:21,
- the method comprises at least one administration cycle, wherein the cycle is a period of eight weeks, wherein for each of the at least one cycles, at least four doses of the anti-LAG-3 antibody are administered at a flat dose of about 1, 3, 10, 20, 50, 80, 100, 130, 150, 180, 200, 240 or 280 mg and at least four doses of the anti-PD- 1 antibody are administered at flat dose of about 50, 80, 100, 130, 150, 180, 200, 240 or 280 mg.
- four doses of the anti-LAG-3 antibody are administered at a dose of 0.01, 0.03, 0.25, 0.1, 0.3, 1 or 3, 5, 8 or 10 mg/kg body weight and four doses of the anti-PD-1 antibody are administered at a dose of 0.1, 0.3, 1, 3, 5, 8 or 10 mg/kg body weight.
- the anti-LAG-3 antibody and anti-PD- 1 antibody are administered at the following doses:
- the anti-LAG-3 antibody and anti-PD-1 antibody are administered at the following doses:
- the dose of the anti-LAG-3 and/or anti-PD- 1 antibody is calculated per body weight, e.g., mg/kg body weight.
- the dose of the anti-LAG-3 and/or anti-PD-1 antibody is a flat- fixed dose.
- the dose of the anti-LAG-3 and/or anti-PD-1 antibody is varied over time.
- the anti-LAG-3 antibody and/or anti-PD-1 antibody may be initially administered at a high dose and may be lowered over time.
- the anti-LAG-3 antibody and/or anti-PD- 1 antibody is initially
- the amount of the anti-LAG-3 and/or anti-PD- 1 antibodies administered is constant for each dose. In another embodiment, the amount of antibody administered varies with each dose. For example, the maintenance (or follow- on) dose of the antibody can be higher or the same as the loading dose which is first administered. In another embodiment, the maintenance dose of the antibody can be lower or the same as the loading dose.
- the anti-LAG-3 and/or anti-PD- 1 antibodies are formulated for intravenous administration.
- the anti-PD- 1 antibody is administered on Days 1, 15, 29, and 43 of each cycle.
- the anti-LAG-3 antibody is administered on Days 1, 15, 29, and 43 of each cycle.
- the anti-LAG-3 and/or anti-PD- 1 antibodies are administered once per week, once every or three two weeks, once per month or as long as a clinical benefit is observed or until there is a complete response, confirmed progressive disease or unmanageable toxicity.
- a cycle of administration is eight weeks, which can be repeated, as necessary.
- the treatment consists of up to 12 cycles.
- 4 doses of the anti-PD- 1 antibody are administered per eight week cycle. In another embodiment, 4 doses of the anti-LAG-3 antibody are administered per eight week cycle.
- the anti-PD- 1 antibody and anti-LAG-3 antibody are administered as a first line of treatment (e.g., the initial or first treatment). In another embodiment, the anti-PD- 1 antibody and anti-LAG-3 antibody are administered as a second line of treatment (e.g., after the initial or first treatment, including after relapse and/or where the first treatment has failed).
- the invention features any of the aforementioned embodiments, wherein the anti-PD- 1 antibody is replaced by, or combined with, an anti-PD-Ll or anti- PD-L2 antibody.
- responses to therapy may include: immune-related criteria for progressive regression
- responses to therapy may include:
- lymph nodes must be non-pathological in size ( ⁇ 10 mm short axis).
- Non-target lesions are not considered in the definition of Stable Disease and Partial Response.
- Patients treated according to the methods disclosed herein preferably experience improvement in at least one sign of cancer.
- improvement is measured by a reduction in the quantity and/or size of measurable tumor lesions.
- lesions can be measured on chest x-rays or CT or MRI films.
- cytology or histology can be used to evaluate responsiveness to a therapy.
- the patient treated exhibits a complete response (CR), a partial response (PR), stable disease (SD), immune-related complete disease (irCR), immune- related partial response (irPR), or immune-related stable disease (irSD).
- the patient treated experiences tumor shrinkage and/or decrease in growth rate, i.e., suppression of tumor growth.
- unwanted cell proliferation is reduced or inhibited.
- one or more of the following can occur: the number of cancer cells can be reduced; tumor size can be reduced; cancer cell infiltration into peripheral organs can be inhibited, retarded, slowed, or stopped; tumor metastasis can be slowed or inhibited; tumor growth can be inhibited; recurrence of tumor can be prevented or delayed; one or more of the symptoms associated with cancer can be relieved to some extent.
- administration of effective amounts of the anti-LAG-3 antibody and anti-PD- 1 antibody according to any of the methods provided herein produces at least one therapeutic effect selected from the group consisting of
- the improvement of clinical benefit rate is about 20% 20%, 30%, 40%, 50%, 60%, 70%, 80% or more compared to an anti-LAG-3 antibody or anti-PD- 1 antibody alone.
- kits which include a pharmaceutical composition containing an anti-LAG-3 antibody, such as BMS-986016, and an anti-PD-1 antibody, such as BMS-936558, and a pharmaceutically- acceptable carrier, in a therapeutically effective amount adapted for use in the preceding methods.
- the kits optionally also can include instructions, e.g., comprising administration schedules, to allow a practitioner ⁇ e.g., a physician, nurse, or patient) to administer the composition contained therein to administer the composition to a patient having cancer ⁇ e.g., a solid tumor).
- the kit also can include a syringe.
- kits include multiple packages of the single-dose pharmaceutical compositions each containing an effective amount of the anti-LAG-3 or anti-PD-1 antibody for a single administration in accordance with the methods provided above.
- Instruments or devices necessary for administering the pharmaceutical composition(s) also may be included in the kits.
- a kit may provide one or more pre-filled syringes containing an amount of the anti-LAG-3 or anti-PD-1 antibody.
- the present invention provides a kit for treating a solid tumor in a human patient, the kit comprising:
- BMS-936558 is a fully human, IgG4 (kappa) isotype monoclonal antibody that binds to PD- 1 with nanomolar affinity as measured by surface plasmon resonance using a Biacore ® biosensor system and a high degree of specificity, thus precluding binding to its ligands PD-L1 and PD-L2.
- BMS-936558 does not bind other related family members, such as BTLA, CTLA-4, ICOS or CD28.
- Pre-clinical testing of BMS-936558 demonstrated that binding to PD- 1 results in enhanced T cell proliferation and release of interferon-gamma (IFN-gamma) in vitro.
- the heavy and light chain amino acid sequences of BMS-936558 are provided in SEQ ID NOs: l and 2, respectively.
- Example 2 In Vivo Toxicity of Anti-PD-1 Antibody Novolumab (BMS-936558)
- the overall safety experience with BMS-936558 is based on experience in approximately 1500 subjects treated to date.
- the safety profile is similar across tumor types.
- the one exception is pulmonary inflammation adverse events (AEs) which may be numerically greater in subjects with NSCLC because in some cases, it can be difficult to distinguish between BMS-936558-related and unrelated causes of pulmonary symptoms and radiographic changes.
- AEs pulmonary inflammation adverse events
- the safety profile is generally consistent across completed and ongoing clinical trials with no maximum tolerated dose reached at any dose tested up to 10 mg/kg. There was no pattern in the incidence, severity, or causality of adverse events to BMS-936558 dose level.
- CA209003 was a Phase 1 multi-dose escalation study in subjects with previously treated advanced or metastatic melanoma, RCC, NSCLC, colorectal cancer, or hormone-refractory prostate cancer.
- subjects were administered BMS- 936558 intravenously every 2 weeks with doses of 0.1, 0.3, 1, 3, or 10 mg/kg.
- No maximum tolerated dose was identified in CA209003.
- the maximum dose level evaluated was 10 mg/kg.
- the incidence, severity, and relationship of adverse events were generally similar across dose levels and tumor types.
- Treatment-related high-grade (Grade 3 or 4) adverse events were reported in 45 (14.8%) of subjects, with the most common being fatigue (1.6%), decreased appetite (1.0%), and diarrhea (1.0%).
- At least one serious adverse event (SAE) was reported for 150 (49.3%) of the 304 subjects at all dose levels.
- Grade 3-4 SAEs were reported for 23 subjects (7.6%).
- Drug-related SAEs of any grade occurred in 11.5% of subjects.
- Grade 3-4 drug-related SAEs reported in at least 2 subjects included diarrhea (3 subjects [1.0%]), pneumonitis (3 subjects [1.0%]), pneumonia (2 subjects [0.7%]), and lipase increased (2 subjects [0.7%]).
- Similar to the overall adverse event profile there was no apparent relationship in the incidence or severity of drug-related adverse events to BMS-936558 dose level. There were no apparent differences in the frequency of adverse events based on subjects' tumor type.
- Selected treatment-related adverse events have occurred with low frequency ( ⁇ 5%), but are considered clinically meaningful because they require greater vigilance for early recognition and prompt intervention.
- These adverse events include alanine aminotransferase (ALT) increased (4.3%), aspartate aminotransferase (AST) increased (3.6%), pneumonitis (3.3%), hypothyroidism (3.0%), hyperthyroidism (1.3%), adrenal insufficiency (0.7%), and colitis (0.7%).
- Grade 3-4 events of pneumonitis were reported in 3 subjects (1.0%) as described above (1 event was Grade 4).
- Grade 3 events of colitis, ALT increased, and AST increased were reported in 2 subjects (0.7%) each.
- Single-dose pharmacokinetics (PK) of BMS-936558 were evaluated in 39 subjects with multiple tumor types in CA209001 in the dose range of 0.3 to 10 mg/kg.
- the median Tmax across dose levels ranged from 1.6 to 3.1 hours with individual values ranging from 0.9 to 7 hours.
- the PK of BMS-936558 was linear in the range of 0.3 to 10 mg/kg with dose-proportional increase in Cmax and AUC(INF) and low to moderate intersubject variability was observed at each dose level (i.e., coefficient of variation [CV] ranging from 16 to 45%).
- Geometric mean clearance (CLT) after a single IV dose ranged from 0.13 to 0.19 mL/h/kg, while mean volume of distribution (Vz) varied between 83 to 113 ml/kg across doses.
- the mean terminal T-HALF of BMS-936558 was 17 to 25 days, consistent with half-life of endogenous IgG4, indicating that the elimination mechanism of BMS-936558 may be similar to IgG4. Both elimination and distribution of BMS- 936558 appeared to be independent of dose within the dose range studied.
- mean T-HALF was 21 - 24 hours and median T-max ranged from 0.6 to 3.3 across dose levels, which aligns with the single dose data.
- BMS-936558 has demonstrated clinical activity in a completed Phase 1 single- dose study and 2 ongoing multiple-dose escalation studies (Phase 1 monotherapy:
- NSCLC Newcastle disease virus
- melanoma melanoma
- RCC Solid Tumors
- BMS-936558 monotherapy every 2 weeks (Q2W) at doses ranging from 0.1 to 10 mg/kg. The majority of responses were durable and exceeded 6 months.
- PFSR progression-free survival rate
- BMS-936558 and ipilimumab suggest an advantage in combining two T cell-targeted therapies for subjects with melanoma.
- BMS-936558 + 3 mg/kg ipilimumab treatment group responses were observed in 5 out of 14 evaluable subjects (35.7%, 1 complete response and 2 partial responses by conventional modified World Health Organization [mWHO] criteria, and 2 partial responses by immune-related mWHO criteria).
- mWHO World Health Organization
- ipilimumab treatment group responses were observed in 9 out of 15 evaluable subjects (60%, 3 CRs and 6 PRs; all by conventional mWHO criteria).
- 3 mg/kg BMS-936558 + 3 mg/kg ipilimumab treatment group objective responses were observed in 4 out of 6 evaluable subjects (66.7%, 3 partial responses by conventional mWHO criteria and 1 partial response by immune-related mWHO criteria). Further details are provided by Wolchok et al. (2013) NEJM 369(2): 122-33, and/or
- BMS-986016 is a fully human antibody specific for human LAG-3 that was isolated from immunized transgenic mice expressing human immunoglobulin genes. It is expressed as an IgG4 isotype antibody that includes a stabilizing hinge mutation (S228P) for attenuated Fc receptor binding in order to reduce or eliminate the possibility of antibody- or complement- mediated target cell killing.
- the heavy and light chain amino acid sequences of BMS-986016 are provided in SEQ ID NOs: 17 and 18, respectively.
- BMS-986016 binds to cynomolgus LAG-3 on transfected CHO cells and on activated cynomolgus T cells with a lower affinity (EC50, 21.5-34.3 nM) than to activated human T cells.
- BMS-986016 promotes the activation of an antigen-specific mouse T cell hybridoma expressing human LAG-3 in co-culture with an MHC class II-positive antigen-presenting cell.
- BMS-986016 enhances activation of human T cells in superantigen stimulation assays when added alone or in combination with BMS-936558 (anti-PD-1 antibody).
- Example 7 Toxicity of Anti-LAG-3 Antibody (BMS-986016) Alone or in Combination with Anti-PD-1 Antibody (BMS-936558)
- lymphoplasmacytic inflammation of the choroid plexus of the brain which was considered non-adverse given the lower severity and incidence of the lymphoplasmacytic inflammation compared to combination treatment with BMS- 986016 and BMS-936558, lack of vasculitis or tissue destruction, and absence of clinical manifestations during the course of treatment.
- BMS-986016 and BMS-936558 100 and 50 mg/kg/week, respectively
- Histopathological findings in this monkey included: slight lymphoplasmacytic inflammation of the choroid plexus; minimal to moderate lymphohistocytic inflammation of the vasculature of the brain parenchyma, meninges, spinal cord (cervical and lumbar); and minimal to moderate mixed cell inflammation of the epididymes, seminal vesicles and testes.
- Clinical pathology changes indicated decreases in red blood cell count, hemoglobin concentration and hematocrit whose cause was unclear, and an increase in fibrinogen correlating with the inflammation observed in the central nervous system (CNS) and male reproductive tract.
- BMS-986016 and BMS-936558 were limited to minimal to slight non-reversible lymphoplasmacytic inflammation of the choroid plexus in the brain in 7 of 8 remaining monkeys, and minimal lymphohistiocytic inflammation of the vasculature of the brain parenchyma in 1 of 8 remaining monkeys, whose reversibility could not be assessed.
- the doses administered are > 10 times higher than the maximum doses proposed for the current study.
- the starting dose of 20 mg (0.25 mg/kg) for BMS-986016 monotherapy (Part A) is less than 1/10 of the human equivalent of the cynomolgus monkey NOAEL (636 mg; 8.0 mg/kg), and is below the HED after a linear adjustment of the NOAEL target exposure for the highest affinity difference estimate of 265-fold (24 mg; 0.30 mg/kg).
- the calculated safety multiple for exposures at the 20 mg (0.25 mg/kg) starting dose is 315-fold based on the cynomolgus monkey NOAEL of 100 mg/kg/week without accounting for affinity differences.
- the starting dose of 3 mg (0.03 mg/kg) for BMS-986016 for the combination therapy (Part B) is based on a linear adjustment of the cynomolgus monkey STD10 for the 265-fold highest affinity difference estimate with an added 10-fold safety factor.
- the maximum recommended starting dose (MRSD) for BMS-986016 based on a 100 mg/kg/week STD10 is 0.03 mg/kg in humans.
- the starting dose of 80 mg (1 mg/kg) for BMS-936558 for the combination therapy (Part B) is based on known human BMS-936558 PK parameters with an added 10-fold safety factor.
- the MRSD for BMS-936558 based on the 50 mg/kg/week cynomolgus monkey STD10 is 4.3 mg/kg in humans, and has been further reduced to identify a dose with acceptable levels of adverse events.
- BMS-986016-FITC Positive staining with BMS-986016-FITC was observed in the plasma membrane or plasma membrane granules following human tissues: mononuclear leukocytes of the urinary bladder, blood cells, colon - large intestine, eye, esophagus, small intestine, stomach, kidney, lung, lymph node, placenta, salivary gland, skin, spleen, thymus, tonsil, uterus - cervix, and uterus - endometrium; and hematopoetic cells of the bone marrow. In addition, staining with BMS-986016-FITC was observed in the cytoplasm of the human pituitary endocrine cell epithelium.
- BMS-986016-FITC staining of human pituitary endocrine cell epithelium cytoplasm and cytoplasmic granules was also anticipated.
- BMS- 986016 is not expected to have access to the cytoplasmic compartment in vivo and the repeat-dose toxicology studies in monkeys showed no effects on the pituitary gland, these findings may be of clinical significance.
- BMS-986016 did not induce cytokine release when presented to human PBMCs regardless of concentration, donor, or incubation time.
- the levels of cytokines observed were either at or near the assay lower limits of quantification with no evidence of dose-dependence or pattern across donors (IL- ⁇ , IL-2, IL-5, IL-10, IL-12p70, and IFN- ⁇ ) or were generally overlapping with cytokine levels from
- PBMCs incubated with negative controls IL-6, IL-8, TNF-a.
- BMS-986016 demonstrated favorable pharmacokinetic (PK) properties in cynomolgus monkeys. From both single-dose and repeat-dose IV PK studies, BMS- 986016 decayed bi-exponentially and the exposure was approximately dose- proportional.
- the systemic clearance (CLTp) ranges from 0.12 to 0.22 mL/h/kg and a terminal half-life (T-HALF) 133 to 414 hours.
- T-HALF terminal half-life
- the volume of distribution at steady state (Vss) was 62 to 72 mL/kg, suggesting limited distribution outside the plasma.
- Anti-BMS-986016 antibodies were detected in some monkeys but the presence of anti-BMS-986016 antibodies appeared to have no impact on BMS-986016 exposure.
- Example 9 Inhibition of Tumor Growth In Vivo by Combination Treatment with Anti-LAG-3 Antibody and Anti-PD-1 Antibody
- anti-LAG-3 antibody resulted in 20%-30% TF mice compared to control and anti-PD- 1 antibody-treated mice (0%-10% TF mice), while the combination of anti-LAG-3 and anti-PD- 1 antibodies resulted in 60%-90% TF mice.
- anti-LAG-3 antibody showed modest tumor growth inhibition alone, but when administered in combination with anti-PD- 1 antibody, resulted in enhanced antitumor activity above that observed for anti-PD- 1 antibody alone (80% vs. 40% TF mice, respectively).
- Example 10 Phase 1 Trial in Patients Having Solid Tumors
- a phase 1 trial of anti-LAG-3 antibody (BMS-986016) and anti-PD-1 antibody (BMS-936558) is conducted in patients having advanced solid tumors to demonstrate the efficacy of administering BMS-986016 and BMS-936558 as a combination treatment.
- the primary objective of the study is to assess the safety and tolerability of BMS-986016 given in combination with BMS-936558 and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination, in subjects with advanced solid tumors.
- DLTs dose limiting toxicities
- MTD maximally tolerated dose
- Secondary objectives include assessing the preliminary anti-tumor activity of the combination of BMS-986016 and BMS-936558 in subjects with advanced solid tumors, characterizing the pharmacokinetics (PK) of BMS-986016 and BMS-936558 when co-administered, monitoring immunogenicity of BMS-986016 and BMS- 936558 administered as combination therapy, and assessing the effect of BMS- 986016 and BMS-936558 on corrected QT ("QTc").
- PK pharmacokinetics
- Additional exploratory objectives include assessing the pharmacodynamic effects of BMS-986016 and BMS- 936558 combination therapy based on select biomarkers in the peripheral blood and tumor biopsy specimens, characterizing T cell function during BMS-986016 and BMS-936558 combination therapy, assessing the 2-year landmark overall survival in subjects treated with BMS-986016 and BMS-936558, exploring preliminary antitumor activity of BMS-986016 and BMS-936558 combination therapy in subjects with advanced solid tumors, characterizing pharmacokinetics and exposure-response relationships in subjects treated with BMS-986016 and BMS-936558, and
- Part A and Part B consist of a 3 + 3 + 3 dose escalation design with BMS-986016 administered as a single agent (Part A) or in combination with BMS-936558 (Part B) in subjects with advanced solid tumors.
- Treatment in Part B is initiated upon the decision to escalate to the third dose cohort in Part A (in accordance with dose escalation rules). Subsequently, escalation in the 2 parts proceeds in parallel.
- Part B the dose of BMS-986016 administered in combination with BMS-936558
- Part A the dose of BMS-986016 that have been demonstrated previously to be safe on the monotherapy dose escalation arm (Part A).
- Part C consists of cohort expansion in 6 disease-restricted populations of
- Treatment in Part C is initiated when the maximum tolerated dose (MTD) (or maximum administered dose (MAD) if no MTD is determined) for Part B has been determined.
- MTD maximum tolerated dose
- MAD maximum administered dose
- the doses selected for Part C do not exceed the Part B MTD or MAD, but dose determination may incorporate assessment of other data, including toxicities and PK and pharmacodynamic data from Parts A and B.
- a schematic of the study is provided in Figure 2.
- Subjects complete up to 4 periods of the study as follows: Screening (up to 28 days), Treatment (up to a maximum of twelve 8-week cycles of study therapy), Clinical Follow-up (135 days), and Survival Follow-up (up to 2 years following the first dose of study drug; a longer follow-up period could be considered in selected cases if an efficacy signal is apparent).
- diagnostic imaging may be performed every 12 weeks until progression in subjects who discontinue due to CR, and in subjects with PR at the end of Cycle 12.
- the Treatment Period consists of up to twelve 8-week treatment cycles. Each treatment cycle is comprised of 4 doses of either BMS-986016 alone (Part A) or in combination with BMS-936558 (Parts B and C), administered on Days 1, 15, 29, and 43 of each treatment cycle. In Parts B and C when both antibodies are administered in combination, nivolumab will be given first followed by BMS-986016 within 30 minutes of completing the infusion of nivolumab. Tumor response is evaluated using RECIST vl. l.
- Subjects are allowed to continue study therapy until the occurrence of either: (1) confirmed complete response (CR), (2) completion of the maximum number of twelve 8-week cycles, (3) progressive disease (PD), (4) clinical deterioration, and/or (5) meeting other criteria for discontinuation. Treatment beyond progression is allowed in select subjects with initial RECIST vl.l -defined PD who are receiving clinical benefit and tolerating treatment. Subjects who discontinue treatment enter a 135-day Clinical Follow-up period.
- Subjects are allowed to continue on therapy for up to twelve 8-week cycles or until confirmed complete response, progressive disease, clinical deterioration, or meeting criteria for discontinuation.
- Subjects may be on study for a total of up to approximately 2.3 years, including a 28-day screening period, up to twelve 8-week cycles of treatment, a 135-day clinical follow-up period, and up to 2 years of follow- up for survival (beginning from the first dose of study drug).
- the total duration of the study is expected to be approximately 5 years from the time of the first visit of the first subject to the required survival follow-up of the last subject enrolled.
- a 3 + 3 + 3 design is used to assess the safety of BMS-986016 given as single agent.
- a fourth subject may be enrolled at the beginning of a dose escalation cohort, if subject is able to start the first day of dosing within approximately one week of the third subject in the same dose escalation cohort.
- the dosages during dose escalation are provided in Figures 2A and 2B and Table 1 (set forth below).
- Three subjects (or 4, if applicable) are initially treated in each dose cohort.
- each of the first 3 subjects (or 4, if applicable) is designated as sentinel subjects and begin a treatment at least 5 days apart. Subjects in subsequent cohorts are not required to observe the 5-day interval between treatment start dates.
- Dose escalation in Part A proceeds as follows: • If 0 of the first 3 subjects (or 4, if applicable) experience a dose-limiting toxicity (DLT) within the DLT evaluation interval, a new cohort of 3 subjects (or 4, if applicable) is treated at the next higher dose level.
- DLT dose-limiting toxicity
- any cohort previously established to be safe is expanded to obtain additional experience or to investigate dose levels intermediate to those defined in the protocol.
- Dose escalation rules (cohort size, DLT evaluation interval, cohort expansion criteria, etc.) apply to these expanded or additional cohorts.
- a maximum of 9 subjects are enrolled in any additional or expanded dose cohorts.
- Treatment in Part B is initiated after the decision is made to escalate to the third dose cohort in Part A (in accordance with dose escalation rules). Subsequently, escalation in the 2 parts proceeds in parallel. At no point does the dose of BMS- 986016 administered in combination with BMS-936558 (Part B) exceed doses of BMS-986016 that have been demonstrated previously to be safe on the monotherapy dose escalation arm (Part A).
- Treatment assignments for subjects eligible for both Part A and Part B alternates between the 2 parts, with consecutively treated subjects assigned to different parts through interactive voice response system (IVRS) whenever possible. If there are no openings available in the part to which the subject is assigned by this algorithm, the subject is assigned to the next open cohort or part.
- IVRS interactive voice response system
- a 3 + 3 + 3 design is also be used in Part B to assess the safety of BMS- 986016 given in combination with nivolumab.
- a fourth subject may be enrolled at the beginning of a dose escalation cohort, if subject is able to start the first day of dosing within approximately one week of the third subject in the same dose escalation cohort.
- the dosages evaluated during dose escalation are provided in Figures 2A and 2B and Table B (set forth below).
- each of the first 3 subjects (or 4, if applicable) in the first dose cohort in Part B will be designated as sentinel subjects and will begin treatment at least 5 days apart.
- 3 n approximately 3-9 20 240
- each of the first 3 subjects begins treatment at least 5 days apart. Subjects in subsequent cohorts are not be required to observe the 5-day interval between treatment start dates.
- Dose escalation in Part B proceeds as described for Part A. If the MTD is exceeded in Dose Cohort 2, the subsequent cohort is treated with 20 mg of BMS- 986016 and 80 mg of BMS-936558. If this dose combination is found to be safe, escalation proceeds at the previously defined BMS-986016 doses, maintaining the BMS-936558 dose at 80 mg. If no MTD is reached through Dose Cohort 5, then additional cohorts of BMS- 986016 given in combination with BMS-936558 are considered based on the aggregate safety experience during dose escalation.
- any cohort previously established to be safe is expanded in order to obtain additional experience or to investigate dose levels intermediate to those defined in the protocol.
- Dose escalation rules (cohort size, DLT evaluation interval, cohort expansion criteria, etc.) apply to these expanded or additional cohorts.
- a maximum of 9 subjects are enrolled in any additional or expanded dose cohorts.
- the purpose of cohort expansion is to gather additional safety, tolerability, preliminary efficacy, pharmacokinetic, and pharmacodynamic information regarding the combination of BMS-986016 and BMS-936558.
- the doses selected for Part C do not exceed the MTD (or MAD if no MTD is determined) in Part B, but may incorporate assessment of other data including toxicities and PK and
- Doses include doses intermediate to those evaluated in Part B. Modeling is used to help inform the selection of the combination dose level to carry forward in Part C if a dose below the MTD is chosen.
- Six expansion cohorts are restricted to the tumor types listed below in Tables 3A and 3B. Continuous evaluation of toxicity events in the cohort expansions is performed throughout enrollment in the expansion cohorts. If, at any time, the aggregate rate of treatment-related toxicities meeting DLT criteria exceeds 33% across all subjects treated in the Part C cohort expansion, further enrollment is interrupted. Depending on the nature and grade of the toxicity and after assessing the risk:benefit ratio, a new dose(s) for all cohorts is initiated at a previously tested lower dose level or at a dose level intermediate to previously tested lower dose levels.
- a BMS-986016 monotherapy cohort is evaluated in cohort expansion.
- This expansion cohort is restricted to the tumor type(s) found to be responsive to BMS- 986016 monotherapy.
- the dose selected for monotherapy expansion does not exceed the Part A MTD (or MAD if no MTD is determined) and incorporates assessment of other data, including toxicities and PK and pharmacodynamic data from Part A.
- the dose selected is intermediate to those tested in Part A. Modeling is used to help inform the selection of the dose level to carry forward in Part C if a dose below the MTD is chosen.
- Table 3A Tumor Types Eligible For Part C— Cohort Expansion Combination Therapy
- NSCLC C naive to ICMARs 3 approximately 16
- NSCLC C anti-PD-1 or anti-PD-Ll antibody as approximately 16 most recent therapy 5
- HPV d -positive head and neck cancer naive to approximately 16 ICMARs 3
- immune cell-modulating antibody regimens such as, but not limited to, ipilimumab, tremelimumab, anti-PD-1, anti-PD-Ll, anti-PD-L2, anti-KIR, anti-CD137, and/or anti-OX40 antibodies.
- Subjects with anti-PD-1 or anti-PD-Ll antibody as most recent therapy are nonresponsive subjects with progression within 16 weeks of starting therapy. Subjects must provide informed consent within 60 days after the last dose of anti-PD-1 or anti-PD-Ll antibody and should not have discontinued antibody therapy due to serious and/or life-threatening toxicity (e.g., dose-limiting toxicity in prior study). Subjects with anti-PD-1 or anti-PD-Ll antibody as most recent therapy cannot have had prior exposure to any other ICMARs.
- d HPV human papilloma virus
- Table 3B Tumor Types Eligible For Part C— Cohort Expansion Combination Therapy Tumor Type Total Subjects
- NSCLC g naive to ICMARs 3 approximately 16
- NSCLC C anti-PD-1 or anti-PD-Ll antibody as approximately 16 most recent therapy b
- ICMARs immune cell-modulating antibody regimens (such as, but not limited to, anti-CTLA-4, and anti-PD-1 or anti-PD-Ll, anti-PD-L2, anti-KIR, anti-CD137, and/or anti-OX40 antibodies)
- ICMARs immune cell-modulating antibody regimens (such as, but not limited to, anti-CTLA-4, and anti-PD-1 or anti-PD-Ll, anti-PD-L2, anti-KIR, anti-CD137, and/or anti-OX40 antibodies)
- Melanoma subjects progressing while-on or after receiving anti-CTLA-4 and anti-PD-1 or anti-PD- Ll antibody therapies (in sequential or combination regimens), are eligible.
- Non-eligible melanoma subjects in this group include those with: 1) last does of anti-CTLA-4 antibody therapy received within 100 days of first dose of study medication; 2) prior exposure to ICMARs other than anti- CTLA-4, anti-PD-1 or anti-PD-Ll antibody therapy regimens; 3)discontinuation from anti-CTLA-4, anti-PD-1 or anti-PD-Ll antibody therapy due to serious and/or life-threatening toxicity (e.g., dose- limiting toxicity in prior exposure),
- NSCLC subjects whose disease progresses while-on or after therapy with anti-PD-1 or anti-PD-Ll antibody as most recent therapy.
- Subject should not have discontinued antibody therapy due to serious and/or life-threatening toxicity (e.g., dose-limiting toxicity in prior study).
- Subjects with anti-PD-1 or anti-PD-Ll antibody as most recent therapy cannot have had prior exposure to any other ICMARs.
- BMS-986016 has the potential to augment the frequency and severity of previously described adverse events associated with BMS-936558, or to produce new toxicities.
- dose-limiting toxicity is determined based on the incidence, intensity, and duration of adverse events that are related to study drug and that occur within 56 days (8 weeks) of initiation of study drug (i.e., the DLT evaluation interval, through the completion of Cycle 1).
- the severity of adverse events is graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
- DLTs that occur at any time, whether during dose escalation (Part A and Part B) or cohort expansion (Part C) result in all study drug(s) being held, pending evaluation of the event's relatedness to study drug.
- Subjects must meet criteria for re-treatment prior to re-initiation of study treatment.
- Subjects who withdraw from the study during the DLT evaluation interval for reasons other than a DLT may be replaced at the same dose level.
- an infusion cannot be administered at a scheduled visit during the DLT evaluation interval, it must be administered as soon as possible. If the delay is between 1 and 7 days, the procedures at the original scheduled visit should be performed and subjects will be considered evaluable for DLT determination. If the delay is more than 7 days, the dose will be considered missed and will not be replaced.
- subjects will be considered evaluable if they have received 3 out of the 4 scheduled BMS-986016 doses in Part A (or 3 out of 4 schedules BMS-986016 and nivolumab doses in Part B) through the 8 week observation period, only if the one missed dose was secondary to progressive disease or non-medical reasons. Unevaluable subjects may be replaced at the same dose level.
- Hepatic, non-hematologic, and hematologic DLTs are defined separately as outlined below.
- Grade 2 eye pain or reduction in visual acuity that does not respond to topical therapy and that does not improve to Grade 1 within 2 weeks of initiation of topical therapy, or • > Grade 3 non-hepatic or non-hematologic toxicity with the exceptions noted below.
- Grade 3 tumor flare defined as pain, irritation, or rash that localizes to sites of known or suspected tumor
- Consent for tumor biopsy samples for Part A or Part B Dose Escalation: Subject must consent to allow the acquisition of existing formalin-fixed paraffin-embedded (FFPE) tumor tissue, either a block or unstained slides, for performance of correlative studies. If an archived sample is not available, subject must consent to allow a pre-treatment tumor biopsy. In either case, study personnel must ensure that the tissue block or slides physically exist prior to initiating therapy. Subjects unable to provide an archived tumor sample and who either do not consent to a pre-treatment tumor biopsy or do not have accessible lesions are not eligible. (However, subjects whose pre- treatment biopsy yields inadequate tissue quantity or quality are not ineligible on this basis alone.)
- Consent for tumor biopsy samples for Part C Cohort Expansion Subjects with melanoma or head and neck tumors: All subjects in the 2 melanoma cohorts and all subjects in the head and neck tumor cohort are required to undergo pre-treatment and on-treatment biopsies; therefore, subjects must have a lesion located such that the specimen can be obtained at acceptable clinical risk as judged by the Investigator. Biopsy sites for any subjects must be distinct from evaluable lesions. Subjects in the melanoma and head and neck cancer cohorts who do not meet these criteria are not eligible; however, subjects whose screening biopsy yields inadequate tissue quantity or quality are not be ineligible on this basis alone.
- Subjects in the remaining cohorts Subject must consent to allow the acquisition of existing formalin-fixed paraffin-embedded (FFPE) tumor tissue, either a block or unstained slides, for performance of correlative studies. If an archived sample is not available, subject must consent to allow a pre-treatment tumor biopsy. In either case, study personnel must ensure that the tissue block or slides physically exist prior to initiating therapy. Subjects unable to provide an archived tumor sample and who either do not consent to a pre-treatment tumor biopsy or do not have accessible lesions are not eligible. (However, subjects whose pre-treatment biopsy yields inadequate tissue quantity or quality are not ineligible on this basis alone.) Biopsies cannot be collected in subjects with a single measureable lesion, even if accessible.
- FFPE formalin-fixed paraffin-embedded
- ICMARs antibody regimens
- CTLA-4 ipilimumab
- tremelimumab anti-PD-1, anti-PD-Ll, anti-PD-L2, anti- KIR, anti-CD137, or anti-OX40 antibodies, are allowed;
- All solid tumor histologies are permitted except for subjects with primary CNS tumors. Subjects with or without prior anti-PD-1 or anti-PD-Ll antibody therapy are eligible. Alternatively, all solid tumor histologies naive to ICMARs such as, but not limited to, anti- CTLA-4, anti-PD-1, anti-PD-Ll, anti-PD-L2, anti-KIR, anti-CD137, or anti-OX40 antibodies, will be permitted except for subjects with primary CNS tumors.
- Subjects without prior anti-PD-1 or anti-PD-Ll antibody therapy cannot have had prior exposure to any other ICMARs such as, but not limited to, ipilimumab, tremelimumab, anti-PD-L2, anti-KIR, anti- CD137, or anti-OX40 antibodies.
- ICMARs such as, but not limited to, ipilimumab, tremelimumab, anti-PD-L2, anti-KIR, anti- CD137, or anti-OX40 antibodies.
- NSCLC subjects whose disease progresses while-on or after therapy with anti-PD-1 or anti-PD-Ll antibody as most recent therapy.
- subjects with prior anti-PD-1 or anti-PD-Ll antibody as most recent therapy (a) Disease is nonresponsive while on anti-PD- 1 or anti-PD-Ll antibody therapy and presents with PD (per RECIST) within 16 weeks of starting therapy.
- anti-CTLA-4 antibody therapy ipilimumab, tremelimumab, anti-PD-L2, anti-KIR, anti-CD137, or anti-OX40 antibodies.
- (b) Melanoma - subjects whose disease is nonresponsive while on anti-PD- 1 or anti-PD-Ll antibody therapy as most recent therapy and presents with PD (per RECIST) within 16 weeks of starting therapy. Subject must provide informed consent within 60 days after last dose of anti-PD- 1 or anti-PD-Ll antibody therapy and should have not discontinued antibody therapy due to serious and/or life-threatening toxicity (e.g., dose-limiting toxicity in prior study). These subjects cannot have had prior exposure to any other ICMARs such as, but not limited to, ipilimumab, tremelimumab, anti-PD-L2, anti-KIR, anti-CD137, or anti-OX40 antibodies.
- ICMARs such as, but not limited to, ipilimumab, tremelimumab, anti-PD-L2, anti-KIR, anti-CD137, or anti-OX40 antibodies.
- subjects whose disease is progressing while on or after receiving anti-CTLA-4 and anti-PD- 1 or anti-PD-Ll antibody therapy are eligible.
- Last dose of anti-CTLA-4 antibody therapy must have been received > 100 days of first dose of study medication.
- Subjects should have not discontinued antibody therapy due to serious and/or life- threatening toxicity (e.g., dose-limiting toxicity in prior study). These subjects cannot have had prior exposure to any ICMARs other than anti-CTLA-4 and PD- 1 or anti-PD-Ll antibody therapy.
- NSCLC Non-small cell lung cancer
- anti-PD- 1 or anti-PD-Ll antibody therapy as most recent therapy and presents with PD (per RECIST) within 16 weeks of starting therapy.
- Subject must provide informed consent within 60 days after last dose of anti-PD- 1 or anti-PD-Ll antibody therapy and should have not discontinued antibody therapy due to serious and/or life-threatening toxicity (e.g., dose-limiting toxicity in prior study). These subjects cannot have had prior exposure to any other ICMARs such as, but not limited to, ipilimumab, tremelimumab, anti-PD-L2, anti-KIR, anti-CD137, or anti-OX40 antibodies.
- ICMARs such as, but not limited to, ipilimumab, tremelimumab, anti-PD-L2, anti-KIR, anti-CD137, or anti-OX40 antibodies.
- NSCLC subjects whose disease progresses while-on or after therapy with anti-PD- 1 or anti-PD-Ll antibody as most recent therapy. Subject should have not discontinued antibody therapy due to serious and/or life-threatening toxicity (e.g., dose- limiting toxicity in prior study). These subjects cannot have had prior exposure to any other ICMARs such as, but not limited to, anti-CTLA-4, anti-PD-L2, anti-KIR, anti-CD137, or anti-OX40 antibodies.
- ICMARs such as, but not limited to, anti-CTLA-4, anti-PD-L2, anti-KIR, anti-CD137, or anti-OX40 antibodies.
- HPV-associated head and neck tumors subjects naive to ICMARs and with HPV positivity as defined by pl6 immunohistochemistry (IHC)-positive and/or HPV- 16 in situ hybridization (ISH)-positive
- IHC immunohistochemistry
- ISH HPV- 16 in situ hybridization
- Histology restricted to squamous cell carcinoma subjects with advanced/metastatic head and neck tumors - naive to ICMARs
- Histology restricted to squamous cell carcinoma subjects with advanced/metastatic head and neck tumors - naive to ICMARs
- Subjects must have received, and then progressed or been intolerant to, at least one standard treatment regimen in the advanced or metastatic setting, if such a therapy exists.
- Subjects with any prior treatment regimens are eligible. The following are not considered separate lines of treatment: addition of a compound to an ongoing regimen, restarting the same regimen after a drug holiday, or switching from IV to oral therapy.
- Presence of at least one lesion with measurable disease as defined by RECIST vl.l criteria for response assessment.
- Subjects with lesions in a previously irradiated field as the sole site of measurable disease are permitted to enroll provided that the lesion(s) have demonstrated clear progression prior to the time of informed consent and can be measured accurately.
- WBCs White blood cells > 2000/ ⁇ (stable off any growth factor within 4 weeks of first study drug administration)
- Subject re-enrollment This study permits the re-enrollment of a subject that has discontinued the study as a pre-treatment failure (i.e., subject has not been randomized / has not been treated). If re-enrolled, the subject must be re- consented.
- WOCBP Women of childbearing potential
- 2 forms of contraception are required.
- One method must be highly effective (failure rate of less than 1% when used consistently and correctly) and the second method may also be highly effective.
- the individual methods of contraception should be determined in consultation with the Investigator.
- WOCBP must follow instructions for birth control for a total of 24 weeks after the last dose of investigational drug (a period of 30 days plus the time required for the investigational drug to undergo 5 half-lives).
- WOCBP Women of childbearing potential
- Menopause is defined as 12 months of amenorrhea in a woman over age 45 in the absence of other biological or physiological causes.
- females under the age of 55 must have a documented serum follicle-stimulating hormone (FSH) level > 40 mlU/mL to confirm menopause.
- FSH serum follicle-stimulating hormone
- Females treated with hormone replacement therapy, (HRT) are likely to have artificially suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH level.
- the duration of the washout period is a function of the type of HRT used.
- the duration of the washout period below are suggested guidelines and the investigators should use their judgement in checking serum FSH levels. If the serum FSH level is >40 mlU/ml at any time during the washout period, the woman can be considered postmenopausal.
- Women who are not of childbearing potential i.e., who are postmenopausal or surgically sterile; and permanently azoospermic men (e.g., bilateral orchiectomy) do not require contraception.
- Women of childbearing potential WOCBP
- Women of childbearing potential are defined as females who have experienced menarche and who have not undergone surgical sterilization (hysterectomy or bilateraloophorectomy) or are not postmenopausal.
- Menopause is defined clinically as 6 months of amenorrhea in a woman over age 45 in the absence of other biological or physiological causes.
- women under the age of 55 must have a documented serum follicle- stimulatinghoraione (FSH) level > 40 mlU/mL to confirm menopause. 7.
- FSH serum follicle- stimulatinghoraione
- Controlled brain metastases are defined as those with no radiographic progression for at least 4 weeks after radiation and/or surgical treatment at the time of consent. Subjects must have been off of steroids for at least 2 weeks prior to informed consent, and have no new or progressive neurological signs and symptoms.
- Subjects with a prior malignancy are excluded, except adequately treated basal cell or squamous cell skin cancer, localized prostate cancer, carcinoma in situ of the cervix or carcinoma in situ of the bladder, or in situ ductal or lobular carcinoma of the breast.
- Subjects with other prior malignancies diagnosed more than 2 years previously (at the time of informed consent) who have received therapy with curative intent with no evidence of disease during the interval who are considered to present a low risk for recurrence are eligible.
- Subjects with any active autoimmune disease or history of known or suspected autoimmune disease with the exception of subjects with isolated vitiligo, resolved childhood asthma/atopy, controlled hypoadrenalism or hypopituitarism, and euthyroid patients with a history of Grave's disease (subjects with controlled hyperthyroidism must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid- stimulating immunoglobulin prior to study drug administration).
- a known or underlying medical condition that could make the administration of study drug hazardous to the subject or could adversely affect the ability of the subject to comply with or tolerate study.
- Uncontrolled or significant cardiovascular disease including, but not limited to, any of the following: Myocardial infarction or stroke/transient ischemic attack (TIA) within the 6 months prior to consent, uncontrolled angina within the 3 months prior to consent, any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes), QTc prolongation > 480 msec, history of other clinically significant heart disease (i.e., cardiomyopathy, congestive heart failure with New York Heart Association [NYHA] functional classification III- IV, pericarditis, significant pericardial effusion).
- TIA Myocardial infarction or stroke/transient ischemic attack
- Cardiovascular disease-related requirement for daily supplemental oxygen is a requirement for daily supplemental oxygen.
- HIV human immunodeficiency virus
- AIDS known acquired immunodeficiency syndrome
- Hepatitis A antibody (HepA IgM) (Note: history of resolved hepatitis A virus infection is not an exclusion criterion), positive test for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antigen, positive test for qualitative hepatitis C viral load (by PCR).
- systemic or topical corticosteroids at immunosuppressive doses > 7.5 mg/day of prednisone or equivalent
- palliative radiation > gamma knife radiosurgery in CNS
- any investigational drug or placebo any anticancer therapy (chemotherapy, biologies, therapeutic vaccines, radiotherapy, or hormonal treatment), non-oncology vaccines containing live virus, allergen hyposensitization therapy, growth factors, e.g., granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM- CSF), erythropoietin, major surgery, or biphosphonates.
- G-CSF granulocyte-colony stimulating factor
- GM- CSF granulocyte macrophage-colony stimulating factor
- erythropoietin major surgery, or biphosphonates.
- receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitors Within 10 weeks prior to study drug administration: receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitors.
- Intrasubject dose escalation of BMS-986016 or BMS-936558 is not permitted in this study. With the possible exception of subjects being treated at a dose level that is subsequently deemed to exceed the MTD, intrasubject dose reduction of BMS- 986016 or BMS-936558 is not permitted.
- the natural history of select adverse events associated with immunotherapy can differ from and be more severe than adverse events caused by other therapeutic classes. Early recognition and management mitigates severe toxicity.
- management algorithms can assist with select toxicities. Toxicities for which management algorithms have been developed include:
- Adverse events are assessed continuously during the study and for 135 days after the last treatment. Adverse events are evaluated according to the NCI CTCAE version 4.0. Adverse events are coded using the most current version of Medical Dictionary for Regulatory Activities (MedDRA) and reviewed for potential significance and importance.
- MedDRA Medical Dictionary for Regulatory Activities
- EGFR epidermal growth factor receptor
- d HER-2 human epidermal growth factor receptor 2 status via IHC and/or ISH
- g hCG beta-human chorionic gonadotrophin
- i IHC and/or ISH pl6 immunohistochemistry (IHC) and/or HPV-16 in situ hybridization (ISH)
- k ALK anaplastic lymphoma kinase
- CA125 cancer antigen 125
- Efficacy is evaluated in Parts A and B (dose escalation), as well as in Part C (cohort expansion). Changes in tumor measurements and tumor response at the time of each assessment are determined.
- the baseline assessment during the screening period requires CT or MRI scans of the chest, abdomen, and pelvis, and other anatomic regions as indicated by individual subject's tumor type and/or disease history. Subsequent timepoints require scans of the chest, abdomen, and pelvis, as well as other anatomic regions that were scanned at baseline based on the individual subject's tumor type and/or disease history. Scans of the brain are otherwise required as clinically indicated.
- Tumor status are assessed at baseline, during treatment (every 8 weeks) for up to twelve 8-week cycles of therapy, and once during follow-up.
- CT and MRI scans re read and assessed locally per RECIST vl.l. All imaging scans are de-identified and archived in their native Digital Imaging and Communications in Medicine (DICOM) format as part of the subject's study file.
- DICOM Digital Imaging and Communications in Medicine
- the efficacy assessments include the ORR (e.g., PR + CR), DOR, and PFSR at landmark timepoints (e.g., 24 weeks), based on assessment of tumor response using irRECIST and RECIST vl.l. Landmark 2-year overall survival (OS).
- ORR e.g., PR + CR
- DOR e.g., DOR
- PFSR e.g., PFSR at landmark timepoints (e.g., 24 weeks), based on assessment of tumor response using irRECIST and RECIST vl.l. Landmark 2-year overall survival (OS).
- Serum samples for BMS-986016 pharmacokinetics and anti-drug antibody (ADA) assessments are collected for all subjects.
- Serum samples for BMS-936558 pharmacokinetics and ADA assessments re collected for all subjects enrolled in Part B and C.
- the serum samples are analyzed for BMS-986016 and BMS-936558 by a validated immunoassay.
- selected serum samples are analyzed by an exploratory orthogonal method (e.g., liquid chromatography [LC]-mass spectrometry [MS]/MS) that measures total BMS-986016 and/or BMS-936558.
- an exploratory orthogonal method e.g., liquid chromatography [LC]-mass spectrometry [MS]/MS
- the pharmacodynamics of BMS-986016 treatment administered alone or in combination with BMS-936558 is assessed by quantifying biomarkers in peripheral blood and tumor tissue in the first 3 subjects enrolled at each dose level during the dose escalation (Parts A and B) and in subjects with melanoma and head and neck cancers during cohort expansion (Part C) phases of the study.
- Parts A and B dose level during the dose escalation
- Part C subjects with melanoma and head and neck cancers during cohort expansion
- a Day 5 visit can occur on Day 3 or Day 4
- a Day 5 visit can occur on Day 3 or Day 4.
- Day 8 visit can occur on Day 7 or Day 9.
- c Day 5 visit can occur on Day 3 or Day 4
- Fresh tumor biopsy is mandatory for subjects with melanoma and head and neck cancer in Part C. Biopsy is obtained at anytime during Cycle 1, Week 8 (Days 50- 56) at the same time as diagnostic imaging.
- PBMC samples only to be collected for subjects in the US, not required for subjects Ex-US.
- c Day 5 visit can occur on Day 3 or Day 4.
- Day 8 visit can occur on Day 7 or Day 9.
- Fresh tumor biopsy is mandatory for subjects with melanoma and head and neck cancer in Part
- Biopsy can be obtained at anytime during Cycle 1, Week 8 (Days 50-56) at same time as diagnostic imaging.
- Soluble Biomarkers (Serum Biomarkers)— Parts A, B, and C
- chemokines Pre-treatment and on-treatment serum levels of chemokines, cytokines, and tumor-associated soluble proteins is assessed by techniques that include, but are not limited to, ELISA or multiplex assays.
- Analytes include markers of inflammation, immune activation, host tumor growth factors, and tumor-derived proteins.
- Antitumor Antibodies (Serum Biomarkers)— Parts A, B, and C
- BMS-986016 and BMS-936558 may result in the generation of novel, or an increase in existing, antibodies to tumor-associated antigens.
- An assessment of antibodies to a panel of > 8000 proteins is performed using pre- treatment and on-treatment serum in multiplex and ELISAs. These data are used to explore if antitumor antibodies are associated with clinical response and safety parameters, as well as inform pharmacodynamics of drug administration.
- Immunophenotyping Flow Cytometry/PBMC
- PBMCs Peripheral blood mononuclear cells
- Subsets of cells characterized by immunophenotyping include naive, activated, and exhausted effector and memory T cell populations, regulatory T cells, and myeloid-derived suppressor cells.
- PBMCs are isolated and cryopreserved.
- the functional status of effector T cells including, but not limited to, IFN- ⁇ and granzyme B, is assessed by flow cytometric staining.
- the expression level of genes related to response to BMS-986016 + BMS- 936558 is quantified by microarray and/or quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis in whole blood and tumor samples. Analysis includes, but is not necessarily be limited to, genes encoding BMS-986016- stimulated effector functions (perforin, granzyme B, and IFN- ⁇ ) and genes encoding T cell co- stimulatory receptors (PD-1, PD-L1, and CTLA-4).
- RT-PCR quantitative reverse transcription polymerase chain reaction
- ctDNA circulating tumor DNA
- BEAMing technology is utilized to count the frequency of mutations in circulation.
- SNP Single Nucleotide Polymorphism Analysis
- Tumor tissue is collected from all subjects in the dose escalation portion of the protocol. Immunohistochemistry is used to assess the number and composition of immune infiltrates to define the immune cell subsets present within FFPE tumor tissue before and potentially after exposure to BMS-986016 and BMS-936558. These IHC analyses include, but are not necessarily be limited to, the following markers: CD4, CD8, LAG-3, MHC II, PD-1, PD-L1, and PD-L2. Correlations between gene expression and IHC expression are made between assays performed if deemed to be informative.
- Paired pre- and on-treatment tumor biopsies are mandatory for all subjects with melanoma or head and neck cancer who are enrolled in Part C (cohort expansion). Subjects for whom adequate paired pre- and on-treatment biopsies are not collected may be replaced.
- Subjects have at least one lesion large enough to undergo repeated biopsies (pre- and on-treatment biopsies) via core needle (minimum size 18 gauge) or have at least 2 distinct lesions eligible for core needle or excisional biopsies.
- the expected core needle length should be greater than 5 mm.
- a punch biopsy is acceptable for cutaneous lesions. Fine needle aspirate biopsies are not accepted.
- At least two core biopsies are taken at each timepoint, but collection of additional cores is strongly encouraged if deemed clinically safe by the investigator.
- An assessment of biopsy quality by a pathologist is strongly encouraged at the time of the procedure. All biopsies collected must have a detailed pathology report submitted with the specimen.
- Tumor biopsy specimens are obtained from consenting subjects prior to and during treatment with BMS-986016 and BMS-936558 to characterize immune cell populations and expression of selected tumor markers.
- Biopsy samples are used for the following assessments: Characterization of TILs and tumor antigens.
- Immunohistochemistry is used to assess the number and composition of immune infiltrates to define the immune cell subsets present within FFPE tumor tissue before and after exposure to BMS- 986016 and nivolumab.
- IHC analyses include, but are not necessarily limited to, the following markers: CD4, CD8, LAG- 3, MHC II, PD-1, PD-L1, and PD-L2. Correlations between gene expression and IHC expression are made between assays performed if deemed to be informative.
- Laser capture microdissection Isolation of tumor and/or TIL on FFPE sections is performed by laser capture microdissection (LCM) for high-throughput profiling of molecular events within the tumor microenvironment.
- LCD laser capture microdissection
- T cell repertoire Characterization of T cell repertoire. DNA sequencing is performed on pre- and post-treatment FFPE tumor tissue to assess the composition of the T cell repertoire. Low T cell receptor diversity may be a poor prognostic factor of overall survival in metastatic breast cancer patients. Currently, there is a poor understanding of T cell receptor diversity as a predictor factor of response to immunotherapy, given that the major mechanism of BMS-936558 and BMS- 986016 is hypothesized to be the functional restoration of T cell antitumor immunity. Therefore, a characterization of the diversity of the T cell compartment in the periphery, and within the tumor, at baseline and on-treatment is performed by T cell receptor next-generation DNA sequencing. T cell repertoire analysis is also performed from DNA isolated from peripheral blood to compare the status of tumor and peripheral T cell repertoire pre and post treatment.
- RNAlater or similar reagent are examined for mRNA gene expression by Affymetrix gene array technology and/or quantitative real-time polymerase chain reaction (qPCR) to detect expression of selected immune-related genes.
- qPCR quantitative real-time polymerase chain reaction
- RNA including CD3, IFN- ⁇ , LAG- 3, and PD-1.
- Subjects whose screening biopsy yields inadequate tissue quantity or quality are allowed to continue in the study. If on-treatment biopsy is not successful, subjects also continue on study. Such subjects are replaced in order to obtain 48 subjects with adequate paired tumor biopsies. If subjects have a response to treatment, on-treatment biopsies might not be possible. In this case, subjects also continue on study.
- the tumor tissue that is obtained from these biopsies is divided equally into FFPE and frozen samples, which can be used for histologic confirmation of melanoma, as well as for the assays listed above.
- Biopsies are done with local anesthesia or conscious sedation. Institutional guidelines for the safe performance of biopsies are followed. Excisional biopsies are performed to obtain tumor biopsy samples. Invasive procedures that require general anesthesia are not performed to obtain a biopsy specimen. However, if a surgical procedure is performed for a clinical indication, excess tumor tissue is used for research purposes with the consent of the subject.
- Serum samples collected at timepoints are analyzed by a validated
- ad hoc serum samples designated for pharmacokinetic or biomarker assessments are used for immunogenicity analysis if required (e.g., insufficient volume for complete immunogenicity assessment or to follow up on suspected immunogenicity related adverse event).
- An adverse event is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.
- An AE is therefore any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product.
- the causal relationship to study drug is determined by a physician and used to assess all adverse events (AE).
- the casual relationship can be one of the following: Related: There is a reasonable causal relationship between study drug administration and the AE.
- SAE serious adverse event
- DILI drug induced liver injury
- SAE nonpathogenic
- DILI drug induced liver injury
- SAEs Any component of a study endpoint that is considered related to study therapy (e.g., death is an endpoint, if death occurred due to anaphylaxis, anaphylaxis must be reported) is reported as SAE.
- the following hospitalizations are not considered SAEs:
- routine health assessment requiring admission for baseline/trending of health status (e.g., routine colonoscopy)
- SAEs whether related or not related to study drug, are collected, including those thought to be associated with protocol-specified procedures. All SAEs are collected that occur during the screening period and within 135 days of discontinuation of dosing. If applicable, SAEs are collected that relate to any later protocol- specified procedure (e.g., a follow-up skin biopsy). All SAEs are followed to resolution or stabilization.
- a nonserious adverse event is an AE not classified as serious.
- the collection of nonserious AE information begins at initiation of study drug and continues for 135 days after discontinuation of dosing. Nonserious AEs are followed to resolution or stabilization, or reported as SAEs if they become serious.
- Follow-up is also required for nonserious AEs that cause interruption or discontinuation of study drug and for those present at the end of study treatment as appropriate. All identified nonserious AEs are recorded and described on the nonserious AE page of the CRF (paper or electronic).
- Dose Escalation (Parts A and B): Sample size at each dose depends on observed toxicity and cannot be precisely determined. Part A and Part B have 3 to 9 subjects in each cohort.
- Cohort Expansion allows for better estimation of the toxicity rate and provide better precision around preliminary estimates of efficacy. If ⁇ 5 of 16 subjects (i.e., -30% of in a cohort) experience a toxicity, there is at least 90% confidence that the true toxicity rate is not greater than 50.4% (based on
- Clopper-Pearson exact binomial 1-sided 90% confidence interval A sample size of 16 subjects per cohort also allows for estimation of the proportion of subjects with objective response (i.e., CR + PR) within a cohort such that the maximum distance between the estimated rate and either limit of the exact 2-sided 95% Clopper-Pearson confidence interval is 27.4%.
- This analysis set includes all subjects who receive either study drug, have a baseline tumor assessment with measurable disease, and one of the following: (1) at least one evaluable on-treatment tumor assessment, (2) clinical progression, or (3) death prior to the first on-treatment tumor evaluation.
- BMS-986016 Pharmacokinetic Analysis Set This analysis set includes all subjects who receive BMS-986016 and have at least one valid PK parameter to be included in statistical analyses of BMS-986016 PK data.
- BMS-986016 Immunogenicity Analysis Set This analysis set includes all subjects who receive BMS-986016 and have at least one BMS-986016 immunogenicity sample available.
- BMS-936558 Immunogenicity Analysis Set This analysis set includes all subjects who receive BMS-936558 and have at least one BMS-936558 immunogenicity sample available.
- the primary endpoint of this Phase 1 study is safety as measured by the rate of AEs, serious adverse events (SAEs), deaths, and laboratory abnormalities (e.g., Grade 3 or higher per CTCAE v 4), assessed during treatment and for up to 135 days of
- BMS-936558 is assessed as a secondary objective using the following endpoints
- Concentration at the end of a dosing interval e.g., concentration at 336
- Efficacy is assessed as a secondary objective using the endpoints described below for irRECIST and RECIST vl .1.
- clinical decision making is based on RECIST.
- Statistical analysis and reporting are based on both criteria.
- Best overall response is the best response designation recorded from the start of the study treatment until the last protocol specified tumor assessment (e.g., 30 day follow-up visit) taking into account any requirement for confirmation, based on RECIST vl.l or irRECIST criteria. CR or PR determinations included in the BOR assessment are confirmed by a consecutive second (confirmatory) evaluation meeting the criteria for response and performed at least 4 weeks after the criteria for response are first met.
- ORR Objective response rate
- Duration of response computed only for subjects with a BOR of CR or PR is defined as the number of days between the date of first response and the subsequent date of objectively documented disease progression based on the criteria (RECIST vl.l or irRECIST) or death, whichever occurs first. For those subjects who remain alive and have not progressed or received subsequent therapy, duration of response is censored on the date of last protocol specified tumor assessment. Subjects who receive subsequent therapy are censored at the start of subsequent therapy.
- PFS Progression-free survival
- the probability is computed based on the number of days between the first dose of study drug and progressive disease (as defined by RECIST or irRECIST) or death. For those subjects who remain alive and have not progressed, PFS is censored on the date of the last protocol specified tumor assessment. These endpoints are determined based on tumor measurements occurring every 8 weffeks during the Treatment Period (up to twelve 8-week cycles), and once during the Clinical Follow-up period (30 days), for a total of ⁇ 1.9 years.
- ADA-positive or ADA-negative individual samples are characterized as ADA-positive or ADA-negative.
- a subject is considered to have a positive sample at baseline if the last sample prior to the initiation of treatment is ADA-positive.
- a post- baseline sample from a subject who is ADA-negative at baseline is considered ADA- positive if ADA is detected.
- a post-baseline sample from a subject who is ADA- positive at baseline is considered ADA-positive if there is a relevant increase in titer (magnitude of the increase in titer considered relevant may vary by drug and assay, and is delineated in the statistical analysis plan).
- relevant ADA endpoints may include:
- QTc is assessed by a central reader at follow-up visit 1, and on day 1 of Cycle 1 and Cycle 3 (pre-dose and 4 hour post-dose time points). These assessments are used to address the secondary objective of assessing the effect of BMS-986016 administered alone and in combination with BMS-936558 on QTc. ECGs assessed locally by the investigator are also collected at the start of each cycle.
- Biomarker endpoints from peripheral blood are generally measured at multiple timepoints, and evaluated as both predictive and pharmacodynamic markers in the context of the exploratory biomarker objectives. These may include measures such as levels and change from baseline in levels of the following at each scheduled timepoint:
- T cell co- stimulatory receptors PD-1, PD-L1, and CTLA-4.
- Endpoints from tumor biopsies are explored predominantly in an effort to identify baseline markers predictive of efficacy, since they are only measured at baseline for most subjects. For the subset of subjects who have both pre-treatment and on-treatment biopsies, pharmacodynamic associations are explored. Endpoints may include measures, such as pre-treatment levels and change in levels observed on- treatment of:
- T cell co- stimulatory receptors PD-1, PD-L1, and CTLA-4.
- IHC assessment of the presence/absence and intensity (measured using a discrete scale: such as 0, 1, 2, 3, 4) of expression of LAG-3, MHC class II, PD-1, PD-L1, and PD-L2.
- BMS-936558 concentration-time data at scheduled trough (Ctrough) and end- of-infusion timepoints is evaluated as an exploratory endpoint. Measurements are collected on treatment (up to 12 cycles) and for up to 135 days during the post- treatment follow-up.
- PK parameters for BMS-986016 are calculated using noncompartmental analyses. Summary statistics are tabulated for the PK parameters of BMS-986016 by dose and study day/cycle. To describe the association of these parameters with dose of BMS-986016, scatter plots of Cmax and AUC(TAU) versus dose are provided for each day/cycle measured. Dose proportionality of BMS-986016 when administered alone or co-administered with BMS-936558 is also assessed based on a power model. Trough concentrations of BMS-986016 re plotted versus study day and cycle. BMS- 936558 end-of-infusion and trough (Ctrough) concentrations are tabulated using summary statistics.
- Anti-PD-1 mAb (BMS936558; 5C4 in WO 2006/121168) (variable region underlined; constant region bold)
- Anti-PD-1 mAb (BMS936558; 5C4 in WO 2006/121168) (variable region underlined; constant region bold)
- Anti-PD-1 mAb (BMS936558; 5C4 in WO 2006/121168)
- Anti-PD-1 mAb (BMS936558; 5C4 in WO 2006/121168)
- Anti-PD-1 mAb (BMS936558; 5C4 in WO 2006/121168)
- VL Light Chain Variable Region
- Anti-PD-1 mAb (BMS936558; 5C4 in WO 2006/121168)
- Anti-PD-1 mAb (BMS936558; 5C4 in WO 2006/121168)
- Anti-LAG-3 mAb (BMS-986016) caggtgcagctacagtggggcgcaggactgttgaagccttcggagaccctgtccct cacctgcgctgtctatggtgggtccttcagtgattactactggaactggatccgccag cccccagggaaggggctggagtggattggggaaatcaatcatcgtggaagcaccaact ccaacccgtccctcaagagtcgagtcaccctatcactagacacgtccaagaaccagtt ctcctgaagctgaggtctgtgaccgccgcggacacggctgtgtattactgtgcgttttgccaggggttgtggttactgtgttggggccagggctgtgtg
- Anti-LAG-3 mAb gaaattgtgttgacacagtctccagccaccctgtctttgtctccaggggaaagagccacc ctctcctgcagggccagtcagagtattagcagctacttagcctggtaccaacagaaacct ggccaggctcccaggctcctcatctatgatgcatccaacagggccactggcatcccag ccaggttcagtggtgggtctgggacagacttcactctcaccatcagcagcctagagc ctgaagattttgcagtttattactgtcagcagcgtagcaactggcctctcacttttggcc aggggaccaacctggagatcaaacgtggtggctgcaccatctgtctcatcatctggccaccatcagcag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (29)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2016003103A MX2016003103A (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors. |
SG11201601763SA SG11201601763SA (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
AU2014323523A AU2014323523B2 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
EA201690617A EA036902B1 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
EP23167891.3A EP4249065A3 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
CA2924524A CA2924524A1 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
BR122023024195-9A BR122023024195A2 (en) | 2013-09-20 | 2014-09-18 | USES OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
KR1020167009856A KR20160055269A (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
JP2016515520A JP6595458B2 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-LAG-3 antibody and anti-PD-1 antibody for treating tumor |
US15/021,102 US10081681B2 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
KR1020227046412A KR20230008255A (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
EP18209399.7A EP3508502B1 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
CN201480063335.6A CN105793287B (en) | 2013-09-20 | 2014-09-18 | Combination anti-LAG-3 antibodies with anti-PD-1 antibodies for treatment of tumors |
EP16197459.7A EP3178849B1 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
EP14786389.8A EP3046939A1 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
PL16197459T PL3178849T3 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
BR112016005816A BR112016005816A2 (en) | 2013-09-20 | 2014-09-18 | COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT TUMORS |
KR1020217037639A KR20210141789A (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
KR1020247006209A KR20240033088A (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
IL290295A IL290295B1 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
IL244547A IL244547B (en) | 2013-09-20 | 2016-03-10 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
US16/376,394 US20200062845A1 (en) | 2013-09-20 | 2019-04-05 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
CY20191100634T CY1121723T1 (en) | 2013-09-20 | 2019-06-19 | COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TUMOR TREATMENT |
IL272149A IL272149B (en) | 2013-09-20 | 2020-01-20 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
AU2020203056A AU2020203056B2 (en) | 2013-09-20 | 2020-05-08 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
US17/018,241 US11274152B2 (en) | 2013-09-20 | 2020-09-11 | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
US17/682,986 US20220185892A1 (en) | 2013-09-20 | 2022-02-28 | Combination of Anti-LAG-3 Antibodies and Anti-PD-1 Antibodies to Treat Tumors |
AU2023200557A AU2023200557A1 (en) | 2013-09-20 | 2023-02-03 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
CY20231100360T CY1126115T1 (en) | 2013-09-20 | 2023-07-25 | COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TUMOR TREATMENT |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361880606P | 2013-09-20 | 2013-09-20 | |
US61/880,606 | 2013-09-20 | ||
US201462014471P | 2014-06-19 | 2014-06-19 | |
US62/014,471 | 2014-06-19 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/021,102 A-371-Of-International US10081681B2 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
US201816108973A Continuation | 2013-09-20 | 2018-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015042246A1 true WO2015042246A1 (en) | 2015-03-26 |
Family
ID=51743546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/056277 WO2015042246A1 (en) | 2013-09-20 | 2014-09-18 | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
Country Status (24)
Country | Link |
---|---|
US (4) | US10081681B2 (en) |
EP (4) | EP3046939A1 (en) |
JP (3) | JP6595458B2 (en) |
KR (4) | KR20210141789A (en) |
CN (2) | CN105793287B (en) |
AU (3) | AU2014323523B2 (en) |
BR (2) | BR112016005816A2 (en) |
CA (1) | CA2924524A1 (en) |
CY (2) | CY1121723T1 (en) |
DK (2) | DK3508502T5 (en) |
EA (1) | EA036902B1 (en) |
ES (2) | ES2728578T3 (en) |
FI (1) | FI3508502T3 (en) |
HR (2) | HRP20230603T1 (en) |
HU (2) | HUE044730T2 (en) |
IL (3) | IL290295B1 (en) |
LT (2) | LT3508502T (en) |
MX (2) | MX2016003103A (en) |
PL (2) | PL3508502T3 (en) |
PT (2) | PT3178849T (en) |
RS (2) | RS64268B1 (en) |
SG (2) | SG10201802264PA (en) |
SI (2) | SI3508502T1 (en) |
WO (1) | WO2015042246A1 (en) |
Cited By (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015116539A1 (en) * | 2014-01-28 | 2015-08-06 | Bristol-Myers Squibb Company | Anti-lag-3 antibodies to treat hematological malignancies |
WO2016110593A1 (en) * | 2015-01-09 | 2016-07-14 | Immutep S.A.S. | Combined preparations for the treatment of cancer or infection |
US9505839B2 (en) | 2012-07-02 | 2016-11-29 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof |
WO2016207646A1 (en) | 2015-06-24 | 2016-12-29 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
WO2017025498A1 (en) * | 2015-08-07 | 2017-02-16 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
US9683048B2 (en) | 2014-01-24 | 2017-06-20 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
WO2017106129A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
WO2017087589A3 (en) * | 2015-11-18 | 2017-07-13 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
WO2017149143A1 (en) | 2016-03-04 | 2017-09-08 | Agency For Science, Technology And Research | Anti-lag-3 antibodies |
WO2017194265A1 (en) | 2016-05-10 | 2017-11-16 | Agency For Science, Technology And Research | Anti-CTLA-4 Antibodies |
WO2017201502A1 (en) | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
WO2017219995A1 (en) * | 2016-06-23 | 2017-12-28 | 江苏恒瑞医药股份有限公司 | Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof |
WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
WO2018006066A1 (en) * | 2016-07-01 | 2018-01-04 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitory immune receptor inhibition methods and compositions |
US9908936B2 (en) | 2014-03-14 | 2018-03-06 | Novartis Ag | Antibody molecules to LAG-3 and uses thereof |
US9938345B2 (en) | 2014-01-23 | 2018-04-10 | Regeneron Pharmaceuticals, Inc. | Human antibodies to PD-L1 |
US9987500B2 (en) | 2014-01-23 | 2018-06-05 | Regeneron Pharmaceuticals, Inc. | Human antibodies to PD-1 |
CN108136003A (en) * | 2015-07-29 | 2018-06-08 | 诺华股份有限公司 | The use in conjunction of anti-PD-1 and anti-M-CSF antibody in treatment of cancer |
WO2018106862A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
CN108348601A (en) * | 2015-07-22 | 2018-07-31 | 索伦托治疗有限公司 | The Antybody therapy agent combined with LAG3 |
US10081681B2 (en) | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
WO2018183928A1 (en) | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2018185135A1 (en) | 2017-04-05 | 2018-10-11 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
WO2018185232A1 (en) * | 2017-04-05 | 2018-10-11 | Symphogen A/S | Combination therapies targeting pd-1, tim-3, and lag-3 |
WO2018217944A1 (en) * | 2017-05-24 | 2018-11-29 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
US10144779B2 (en) | 2015-05-29 | 2018-12-04 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
WO2018222722A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
WO2018226336A1 (en) | 2017-06-09 | 2018-12-13 | Providence Health & Services - Oregon | Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer |
US10160806B2 (en) | 2014-06-26 | 2018-12-25 | Macrogenics, Inc. | Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof |
US10174113B2 (en) | 2015-04-28 | 2019-01-08 | Bristol-Myers Squibb Company | Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody |
US10188730B2 (en) | 2014-08-19 | 2019-01-29 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
US10189904B2 (en) | 2012-02-15 | 2019-01-29 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
JP2019050804A (en) * | 2016-05-18 | 2019-04-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anti-pd1 and anti-lag3 antibodies for cancer treatment |
WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | Methods of treating tumor |
JP2019514844A (en) * | 2016-03-04 | 2019-06-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Combination therapy with anti-CD73 antibody |
WO2019129137A1 (en) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anti-lag-3 antibody and uses thereof |
US10344090B2 (en) | 2013-12-12 | 2019-07-09 | Shanghai Hangrui Pharmaceutical Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
US10358495B2 (en) | 2015-10-09 | 2019-07-23 | Regeneron Pharmaceuticals, Inc. | Anti-LAG3 antibodies and uses thereof |
US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
WO2019179422A1 (en) * | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/lag-3 antibody molecules |
WO2019191676A1 (en) | 2018-03-30 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of treating tumor |
US10457725B2 (en) | 2016-05-13 | 2019-10-29 | Regeneron Pharmaceuticals, Inc. | Methods of treating skin cancer by administering a PD-1 inhibitor |
US10472419B2 (en) | 2014-01-31 | 2019-11-12 | Novartis Ag | Antibody molecules to TIM-3 and uses thereof |
WO2019224275A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
WO2019241098A1 (en) * | 2018-06-11 | 2019-12-19 | Yale University | Novel immune checkpoint inhibitors |
US10512689B2 (en) | 2015-04-17 | 2019-12-24 | Bristol-Myers Squibb Company | Compositions comprising a combination of nivolumab and ipilimumab |
WO2020002905A1 (en) | 2018-06-25 | 2020-01-02 | Immodulon Therapeutics Limited | Cancer therapy |
US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
US10577422B2 (en) | 2015-07-30 | 2020-03-03 | Macrogenics, Inc. | PD-1-binding molecules and methods of use thereof |
WO2020081928A1 (en) * | 2018-10-19 | 2020-04-23 | Bristol-Myers Squibb Company | Combination therapy for melanoma |
US10736940B2 (en) | 2013-12-19 | 2020-08-11 | Immutep S.A.S. | Combined preparations for the treatment of cancer |
WO2020232019A1 (en) * | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
EP3322731B1 (en) | 2015-07-14 | 2021-01-13 | Bristol-Myers Squibb Company | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) |
US10905784B2 (en) | 2017-02-10 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-LAG3 antibodies for immuno-PET imaging |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
EP3288980B1 (en) | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
WO2021055994A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
WO2021092380A1 (en) | 2019-11-08 | 2021-05-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
WO2021104834A1 (en) | 2019-11-27 | 2021-06-03 | Adc Therapeutics Sa | Combination therapy |
US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
US11072654B2 (en) | 2014-07-17 | 2021-07-27 | Novo Nordisk A/S | Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity |
US11072653B2 (en) | 2015-06-08 | 2021-07-27 | Macrogenics, Inc. | LAG-3-binding molecules and methods of use thereof |
WO2021147837A1 (en) | 2020-01-21 | 2021-07-29 | 上海复宏汉霖生物技术股份有限公司 | Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof |
US11078278B2 (en) | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
WO2022008519A1 (en) | 2020-07-07 | 2022-01-13 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022047189A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
US11344620B2 (en) | 2014-09-13 | 2022-05-31 | Novartis Ag | Combination therapies |
US11352440B2 (en) | 2014-11-21 | 2022-06-07 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
US11359018B2 (en) | 2016-11-18 | 2022-06-14 | Symphogen A/S | Anti-PD-1 antibodies and compositions |
WO2022136255A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022136266A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022136257A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022146947A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
US11390679B2 (en) | 2017-08-30 | 2022-07-19 | Phanes Therapeutics, Inc. | Anti-LAG-3 antibodies and uses thereof |
EP3816187A4 (en) * | 2018-06-29 | 2022-08-03 | Y-Biologics Inc. | Monoclonal antibody specifically binding to lag-3 and use thereof |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
WO2022261018A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
US11607453B2 (en) | 2017-05-12 | 2023-03-21 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2023061930A1 (en) | 2021-10-11 | 2023-04-20 | BioNTech SE | Therapeutic rna for lung cancer |
RU2795232C2 (en) * | 2017-04-05 | 2023-05-02 | Симфоген А/С | Combined medicinal products targeting pd-1, tim-3 and lag-3 |
WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
US11655295B2 (en) | 2018-01-18 | 2023-05-23 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-LAG-3 antibody and use thereof |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
US11732044B2 (en) | 2017-12-27 | 2023-08-22 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-LAG-3 antibody and use thereof |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
EP3631454B1 (en) * | 2017-05-30 | 2023-09-13 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
US11807692B2 (en) | 2018-09-25 | 2023-11-07 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
US11834503B2 (en) | 2016-10-13 | 2023-12-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anti-lag-3 antibodies and compositions |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
US11858994B2 (en) | 2017-03-15 | 2024-01-02 | Repertoire Genesis Incorporation | Biomarkers for cancer immunotherapy |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
EP4161964A4 (en) * | 2020-06-05 | 2024-02-07 | Beijing Mabworks Biotech Co., Ltd | Antibodies binding lag3 and uses thereof |
US11976125B2 (en) | 2017-10-13 | 2024-05-07 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
WO2024137776A1 (en) | 2022-12-21 | 2024-06-27 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
US12054557B2 (en) | 2015-12-22 | 2024-08-06 | Regeneron Pharmaceuticals, Inc. | Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer |
WO2024175699A1 (en) * | 2023-02-23 | 2024-08-29 | Imcheck Therapeutics | Combination of btn3a activating antibody and immune checkpoint inhibitors |
US12084518B2 (en) | 2015-05-21 | 2024-09-10 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL295002A (en) * | 2015-05-12 | 2022-09-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer comprising a pd-l1 binding antagonist |
SG10201913303XA (en) | 2015-07-13 | 2020-03-30 | Cytomx Therapeutics Inc | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
TWI843168B (en) | 2016-10-11 | 2024-05-21 | 美商艾吉納斯公司 | Anti-lag-3 antibodies and methods of use thereof |
JP2020514370A (en) * | 2017-03-17 | 2020-05-21 | キュアバック アーゲー | RNA vaccines and immune checkpoint inhibitors for combination anti-cancer therapy |
ES2928718T3 (en) | 2017-04-03 | 2022-11-22 | Hoffmann La Roche | Immunoconjugates of an anti-PD-1 antibody with a mutant IL-2 or with IL-15 |
KR102408873B1 (en) | 2017-04-05 | 2022-06-15 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies specifically binding to pd1 and lag3 |
US11596696B2 (en) | 2017-04-20 | 2023-03-07 | Adc Therapeutics Sa | Combination therapy with an anti-CD25 antibody-drug conjugate |
TWI791519B (en) * | 2017-04-27 | 2023-02-11 | 美商提薩羅有限公司 | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
CN110913906A (en) | 2017-05-02 | 2020-03-24 | 默沙东公司 | Formulations of anti-LAG 3 antibodies and co-formulations of anti-LAG 3 antibodies with anti-PD-1 antibodies |
JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
CN108864287B (en) * | 2017-05-16 | 2022-08-30 | 上海恒润达生生物科技股份有限公司 | Mesothelin-targeted chimeric antigen receptor, and two modification methods and application thereof |
WO2018213297A1 (en) | 2017-05-16 | 2018-11-22 | Bristol-Myers Squibb Company | Treatment of cancer with anti-gitr agonist antibodies |
EP4245375A3 (en) * | 2017-05-30 | 2023-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
CN111094339B (en) * | 2017-10-17 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | Application of anti-PD-1 antibody and anti-LAG-3 antibody in preparation of medicine for treating tumor |
CN109970857B (en) * | 2017-12-27 | 2022-09-30 | 信达生物制药(苏州)有限公司 | anti-PD-L1 antibodies and uses thereof |
JP7438180B2 (en) * | 2018-03-20 | 2024-02-26 | ウーシー バイオロジクス アイルランド リミテッド | Novel anti-LAG-3 antibody polypeptide |
EP3826660A1 (en) * | 2018-07-26 | 2021-06-02 | Bristol-Myers Squibb Company | Lag-3 combination therapy for the treatment of cancer |
US20210317214A1 (en) * | 2018-09-13 | 2021-10-14 | Merck Sharp & Dohme Corp. | Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancer |
MX2021005266A (en) * | 2018-11-05 | 2021-06-18 | Merck Sharp & Dohme Llc | Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer. |
MX2021005394A (en) * | 2018-11-07 | 2021-07-06 | Merck Sharp & Dohme Llc | Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies. |
CN112079925A (en) * | 2019-06-13 | 2020-12-15 | 上海健信生物医药科技有限公司 | LAG-3 targeting antibodies and bispecific antibodies and uses thereof |
CN112852740A (en) * | 2019-11-27 | 2021-05-28 | 深圳市菲鹏生物治疗股份有限公司 | CAR-T cells and methods of detection |
KR20220119694A (en) * | 2019-12-23 | 2022-08-30 | 마크로제닉스, 인크. | therapy for cancer |
WO2022188867A1 (en) * | 2021-03-12 | 2022-09-15 | 中山康方生物医药有限公司 | Method for improving safety of drug containing immunoglobulin fc fragment |
MX2024003936A (en) * | 2021-09-29 | 2024-06-28 | Akeso Biopharma Inc | Anti-lag3 antibody, pharmaceutical composition and use. |
CN115845051B (en) * | 2022-12-28 | 2024-02-02 | 广州誉衡生物科技有限公司 | Pharmaceutical composition and pharmaceutical preparation and application thereof in treating liver cancer |
WO2024173876A1 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003099196A2 (en) | 2002-05-23 | 2003-12-04 | Cure Tech Ltd. | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
WO2006121168A1 (en) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
US7635757B2 (en) | 1999-08-23 | 2009-12-22 | Dana-Farber Cancer Institute, Inc. | B7-4 Antibodies and uses therefor |
US20090317368A1 (en) | 1999-11-30 | 2009-12-24 | Lieping Chen | B7-h1, a novel immunoregulatory molecule |
WO2010019570A2 (en) * | 2008-08-11 | 2010-02-18 | Medarex, Inc. | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
US7943743B2 (en) | 2005-07-01 | 2011-05-17 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
WO2011161699A2 (en) | 2010-06-25 | 2011-12-29 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2014008218A1 (en) * | 2012-07-02 | 2014-01-09 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2656800B1 (en) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | NEW PROTEINS PRODUCED BY HUMAN LYMPHOCYTES, DNA SEQUENCE ENCODING THESE PROTEINS AND PHARMACEUTICAL AND BIOLOGICAL APPLICATIONS. |
US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
USRE38313E1 (en) | 1994-05-06 | 2003-11-11 | Institut Gustave Roussy | Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies |
PT843557E (en) | 1995-07-21 | 2003-03-31 | Applied Research Systems | METHODS FOR DETECTING ISOLAR INDENTIFYING AND LABELING AND SELECTING TH1 LYMPOCHOCYTES BY INTERMEDIATE LAG-3 PROTEIN |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
KR19990087557A (en) | 1996-03-07 | 1999-12-27 | 그윈넬 해리 제이 | Ribbon for thermal transfer printing and display of near-infrared fluorescent secrets |
AU728911B2 (en) | 1996-11-28 | 2001-01-18 | Institut Gustave Roussy | Mutants of the LAG-3 proteins, products for the expression of these mutants and use |
ATE271607T1 (en) | 1996-11-29 | 2004-08-15 | Applied Research Systems | PREVENTING GRAVE RECOVERY IN TRANSPLANTS AND FOR PRODUCING UNIVERSAL GENE THERAPY HOST CELL, USING LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) |
AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
EP0900841A1 (en) | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
PT2112166T (en) | 1998-12-23 | 2019-01-30 | Pfizer | Human monoclonal antibodies to ctla-4 |
GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
KR100942863B1 (en) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | Human ctla-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
WO2002002641A1 (en) | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
JP3523245B1 (en) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | Transgenic chromosome-introduced rodents for the production of human antibodies |
US7538206B2 (en) | 2001-02-22 | 2009-05-26 | Institut Pasteur | Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
US20020146753A1 (en) | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
AU2002341752B2 (en) | 2001-09-19 | 2008-04-03 | Alexion Pharmaceuticals, Inc. | Engineered templates and their use in single primer amplification |
ATE519779T1 (en) | 2001-09-19 | 2011-08-15 | Roussy Inst Gustave | PROTEINS AND PEPTIDES BINDING TO THE GLU-PRO MOTIV, THERAPEUTIC COMPOSITIONS CONTAINING THEM AND THEIR APPLICATIONS |
EP2388265A1 (en) | 2002-02-22 | 2011-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
AU2003230874A1 (en) | 2002-04-16 | 2003-11-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
EP2322200A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2005035732A2 (en) | 2003-02-19 | 2005-04-21 | Dyax Corporation | Papp-a ligands |
PT1897548E (en) | 2003-02-28 | 2013-11-19 | Univ Johns Hopkins | T cell regulation |
US8119340B2 (en) | 2003-10-08 | 2012-02-21 | The Feinstein Institute For Medical Research | Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia |
EP1711207B1 (en) | 2003-12-10 | 2012-11-28 | Medarex, Inc. | Interferon alpha antibodies and their uses |
MX370489B (en) * | 2004-01-09 | 2019-12-16 | Pfizer | ANTIBODIES TO MAdCAM. |
RU2368622C2 (en) | 2004-04-13 | 2009-09-27 | Ф.Хоффманн-Ля Рош Аг | Antibodies to p-selectin |
JP5848861B2 (en) | 2004-04-20 | 2016-01-27 | ジェンマブ エー/エスGenmab A/S | Human monoclonal antibody against CD20 |
EP1967529A1 (en) | 2004-07-20 | 2008-09-10 | Symphogen A/S | Anti-rhesus D recombinant polyclonal antibody and methods of manufacture |
EP1807451A2 (en) | 2004-08-03 | 2007-07-18 | Dyax Corporation | Hk1-binding proteins |
WO2006029219A2 (en) | 2004-09-08 | 2006-03-16 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
MX2007003533A (en) | 2004-10-01 | 2007-05-23 | Medarex Inc | Methods of treating cd30 positive lymphomas. |
US7892540B2 (en) | 2004-10-06 | 2011-02-22 | Mayo Foundation For Medical Education And Research | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
KR20070108259A (en) | 2005-03-23 | 2007-11-08 | 화이자 프로덕츠 인크. | Therapy of prostate cancer with ctla4 antibodies and hormonal therapy |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
EP1966241A2 (en) | 2005-12-05 | 2008-09-10 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
CN101490085A (en) * | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | Single-chain multivalent binding proteins with effector function |
JP5382692B2 (en) | 2006-07-10 | 2014-01-08 | 学校法人藤田学園 | Antibody classification method, antigen identification method, antibody or antibody set acquisition method, antibody panel preparation method, and antibody or antibody set and use thereof |
WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
JP5456658B2 (en) | 2007-03-30 | 2014-04-02 | メディミューン,エルエルシー | Antibody preparation |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
ES2573458T3 (en) | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Improvement of the stimulatory capacity of the T cells of cells presenting human antigen and their use in vaccination |
AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
CN102666583B (en) | 2009-07-15 | 2015-11-25 | Aimm医疗股份公司 | Gram positive bacterium specificity combinating compound |
EP2593475B1 (en) | 2010-07-14 | 2016-03-02 | Merck Sharp & Dohme Corp. | Anti-addl monoclonal antibody and uses thereof |
WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
ES2692379T3 (en) * | 2010-11-01 | 2018-12-03 | Symphogen A/S | Anti-HER3 antibodies and compositions |
EP3378489A1 (en) * | 2011-10-26 | 2018-09-26 | Elanco Tiergesundheit AG | Monoclonal antibodies and methods of use |
SG11201407190TA (en) | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
NZ711355A (en) | 2013-03-15 | 2020-06-26 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 binding proteins |
WO2015016718A1 (en) * | 2013-08-02 | 2015-02-05 | Bionovion Holding B.V. | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
ES2728578T3 (en) | 2013-09-20 | 2019-10-25 | Bristol Myers Squibb Co | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
EP3556775B1 (en) | 2014-01-28 | 2021-11-17 | Bristol-Myers Squibb Company | Anti-lag-3 antibodies to treat hematological malignancies |
ES2813580T3 (en) | 2015-04-17 | 2021-03-24 | Bristol Myers Squibb Co | Compositions comprising a combination of ipilimumab and nivolumab |
TWI756187B (en) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | Anti-lag3 antibodies and uses thereof |
HRP20231457T1 (en) | 2017-05-30 | 2024-05-10 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
EP4245375A3 (en) | 2017-05-30 | 2023-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
CN110678200B (en) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody |
EP3826660A1 (en) | 2018-07-26 | 2021-06-02 | Bristol-Myers Squibb Company | Lag-3 combination therapy for the treatment of cancer |
SG11202102864XA (en) | 2018-10-19 | 2021-05-28 | Bristol Myers Squibb Co | Combination therapy for melanoma |
-
2014
- 2014-09-18 ES ES16197459T patent/ES2728578T3/en active Active
- 2014-09-18 PL PL18209399.7T patent/PL3508502T3/en unknown
- 2014-09-18 HU HUE16197459 patent/HUE044730T2/en unknown
- 2014-09-18 EP EP14786389.8A patent/EP3046939A1/en not_active Withdrawn
- 2014-09-18 CN CN201480063335.6A patent/CN105793287B/en active Active
- 2014-09-18 EP EP23167891.3A patent/EP4249065A3/en active Pending
- 2014-09-18 ES ES18209399T patent/ES2947575T3/en active Active
- 2014-09-18 EP EP18209399.7A patent/EP3508502B1/en active Active
- 2014-09-18 JP JP2016515520A patent/JP6595458B2/en active Active
- 2014-09-18 BR BR112016005816A patent/BR112016005816A2/en active Search and Examination
- 2014-09-18 KR KR1020217037639A patent/KR20210141789A/en not_active Application Discontinuation
- 2014-09-18 LT LTEP18209399.7T patent/LT3508502T/en unknown
- 2014-09-18 CA CA2924524A patent/CA2924524A1/en active Pending
- 2014-09-18 SI SI201432027T patent/SI3508502T1/en unknown
- 2014-09-18 PL PL16197459T patent/PL3178849T3/en unknown
- 2014-09-18 DK DK18209399.7T patent/DK3508502T5/en active
- 2014-09-18 FI FIEP18209399.7T patent/FI3508502T3/en active
- 2014-09-18 LT LTEP16197459.7T patent/LT3178849T/en unknown
- 2014-09-18 CN CN202010962676.4A patent/CN112516302A/en active Pending
- 2014-09-18 MX MX2016003103A patent/MX2016003103A/en unknown
- 2014-09-18 PT PT16197459T patent/PT3178849T/en unknown
- 2014-09-18 SI SI201431181T patent/SI3178849T1/en unknown
- 2014-09-18 PT PT182093997T patent/PT3508502T/en unknown
- 2014-09-18 SG SG10201802264PA patent/SG10201802264PA/en unknown
- 2014-09-18 RS RS20230454A patent/RS64268B1/en unknown
- 2014-09-18 IL IL290295A patent/IL290295B1/en unknown
- 2014-09-18 SG SG11201601763SA patent/SG11201601763SA/en unknown
- 2014-09-18 KR KR1020167009856A patent/KR20160055269A/en active Application Filing
- 2014-09-18 EP EP16197459.7A patent/EP3178849B1/en active Active
- 2014-09-18 HR HRP20230603TT patent/HRP20230603T1/en unknown
- 2014-09-18 US US15/021,102 patent/US10081681B2/en active Active
- 2014-09-18 RS RS20190508A patent/RS58705B1/en unknown
- 2014-09-18 KR KR1020247006209A patent/KR20240033088A/en active Application Filing
- 2014-09-18 DK DK16197459.7T patent/DK3178849T3/en active
- 2014-09-18 BR BR122023024195-9A patent/BR122023024195A2/en unknown
- 2014-09-18 WO PCT/US2014/056277 patent/WO2015042246A1/en active Application Filing
- 2014-09-18 EA EA201690617A patent/EA036902B1/en not_active IP Right Cessation
- 2014-09-18 HU HUE18209399A patent/HUE062317T2/en unknown
- 2014-09-18 KR KR1020227046412A patent/KR20230008255A/en not_active Application Discontinuation
- 2014-09-18 AU AU2014323523A patent/AU2014323523B2/en active Active
-
2016
- 2016-03-09 MX MX2021002728A patent/MX2021002728A/en unknown
- 2016-03-10 IL IL244547A patent/IL244547B/en active IP Right Grant
-
2019
- 2019-04-05 US US16/376,394 patent/US20200062845A1/en not_active Abandoned
- 2019-04-26 HR HRP20190774TT patent/HRP20190774T1/en unknown
- 2019-06-19 CY CY20191100634T patent/CY1121723T1/en unknown
- 2019-09-26 JP JP2019175292A patent/JP7163260B2/en active Active
-
2020
- 2020-01-20 IL IL272149A patent/IL272149B/en unknown
- 2020-05-08 AU AU2020203056A patent/AU2020203056B2/en active Active
- 2020-09-11 US US17/018,241 patent/US11274152B2/en active Active
-
2022
- 2022-02-28 US US17/682,986 patent/US20220185892A1/en active Pending
- 2022-10-19 JP JP2022167436A patent/JP7480248B2/en active Active
-
2023
- 2023-02-03 AU AU2023200557A patent/AU2023200557A1/en active Pending
- 2023-07-25 CY CY20231100360T patent/CY1126115T1/en unknown
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7635757B2 (en) | 1999-08-23 | 2009-12-22 | Dana-Farber Cancer Institute, Inc. | B7-4 Antibodies and uses therefor |
US20090317368A1 (en) | 1999-11-30 | 2009-12-24 | Lieping Chen | B7-h1, a novel immunoregulatory molecule |
WO2003099196A2 (en) | 2002-05-23 | 2003-12-04 | Cure Tech Ltd. | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
WO2006121168A1 (en) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
US8008449B2 (en) | 2005-05-09 | 2011-08-30 | Medarex, Inc. | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
US7943743B2 (en) | 2005-07-01 | 2011-05-17 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
US20110150892A1 (en) | 2008-08-11 | 2011-06-23 | Medarex, Inc. | Human antibodies that bind lymphocyte activation gene-3 (lag-3) and uses thereof |
WO2010019570A2 (en) * | 2008-08-11 | 2010-02-18 | Medarex, Inc. | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
WO2011161699A2 (en) | 2010-06-25 | 2011-12-29 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2014008218A1 (en) * | 2012-07-02 | 2014-01-09 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
Non-Patent Citations (64)
Title |
---|
AGATA ET AL., INT IMMUNOL, vol. 8, 1996, pages 765 - 72 |
AGRAWAL, S., FEN Y., KOLLIA G., SAEGER S., ULLMANN., MCDONALD D., GUPTA A. K., ROY A., MASSON E.: "Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody.", XP002734393, Retrieved from the Internet <URL:http://meetinglibrary.asco.org/content/98623-114> [retrieved on 20150113] * |
BENNETT ET AL., J IMMUNOL, vol. 170, 2003, pages 711 - 8 |
BETTINI M. ET AL., J. IMMUNOL., vol. 187, 2011, pages 3493 - 3498 |
BLACKBURN SD ET AL., NAT. IMMUNOL., vol. 10, 2009, pages 29 - 37 |
BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 54, 2005, pages 307 - 314 |
BOYD, EDITH: "University of Minnesota. The Institute of Child Welfare, Monograph Series, No. x", 1935, OXFORD UNIVERSITY PRESS |
BRISTOL-MYERS SQUIBB: "View of NCT01968109 on 2014_06_20", 20 June 2014 (2014-06-20), XP002734391, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01968109/2014_06_20> [retrieved on 20150113] * |
BRISTOL-MYERS SQUIBB: "View of NCT02061761 on 2014_08_28", 28 August 2014 (2014-08-28), XP002734392, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT02061761/2014_08_28> [retrieved on 20150113] * |
BROWN ET AL., J. IMMUNOL., vol. 170, 2003, pages 1257 - 66 |
CAMISASCHI C ET AL., J. IMMUNOL., vol. 184, 2010, pages 6545 - 6551 |
CARTER ET AL., EUR J IMMUNOL, vol. 32, 2002, pages 634 - 43 |
CURRENT, JD, THE INTERNET JOURNAL OFANESTHESIOLOGY, vol. 2, no. 2, 1998 |
DONG ET AL., J. MOL. MED., vol. 81, 2003, pages 281 - 7 |
DONG ET AL., NAT. MED., vol. 8, 2002, pages 787 - 9 |
DONG H ET AL., NAT MED, vol. 8, 2002, pages 793 - 800 |
DONG H ET AL., NAT MED., vol. 5, 1999, pages 1365 - 1369 |
DU BOIS D; DU BOIS EF, ARCHIVES OF INTERNAL MEDICINE, vol. 17, no. 6, June 1916 (1916-06-01), pages 863 - 71 |
FREEMAN ET AL., J EXP MED, vol. 192, 2000, pages 1027 - 34 |
FUJIMOTO S ET AL., NIPPON EISEIGAKU ZASSHI, vol. 5, 1968, pages 443 - 50 |
GANDHI MK ET AL., BLOOD, vol. 108, 2006, pages 2280 - 2289 |
GEHAN EA; GEORGE SL, CANCER CHEMOTHER REP, vol. 54, 1970, pages 225 - 235 |
GODING SR ET AL., J. IMMUNOL., vol. 190, no. 9, 2013, pages 4899 - 4909 |
GODING STEPHEN R ET AL: "Combination of adoptive cell transfer, anti-PD-L1 and anti-LAG-3 antibodies for the treatment of recurrent tumors Better with more", ONCOIMMUNOLOGY, vol. 2, no. 8, August 2013 (2013-08-01), XP002734389 * |
GROSSO JF ET AL., J. CLIN. INVEST., vol. 117, 2007, pages 3383 - 3392 |
HAMID O ET AL., NEJM, vol. 369, 2013, pages 134 - 144 |
HANSEN ET AL., IMMUNOGENICS, vol. 10, 1980, pages 247 - 260 |
HAYCOCK GB ET AL., J PEDIATR, vol. 93, 1978, pages 62 - 66 |
HUANG CT ET AL., IMMUNITY, vol. 21, 2004, pages 503 - 513 |
HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 263 - 266 |
ISHIDA ET AL., EMBO J, vol. 11, 1992, pages 3887 - 95 |
IWAI ET AL., PROC. NAT'L. ACAD. SCI. USA, vol. 99, 2002, pages 12293 - 7 |
KEIR ME ET AL., ANNU REV IMMUNOL, vol. 26, 2008, pages 677 - 704 |
KONISHI ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 5094 - 100 |
LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 8 |
LYFORD-PIKE S ET AL., CANCER RES., vol. 73, no. 6, 2013, pages 1733 - 41 |
MATSUZAKI J ET AL., PROC. NATL. ACAD. SCI., U S A, vol. 107, 2010, pages 7875 - 7880 |
MOSTELLER RD., N ENAL J MED., vol. 317, 1987, pages 1098 |
NIELSEN ET AL., LUPUS, vol. 13, 2004, pages 510 |
NISHIMURA ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 51 |
NISHIMURA ET AL., SCIENCE, vol. 291, 2001, pages 319 - 22 |
NISHIMURA H ET AL., IMMUNITY, vol. 11, 1999, pages 141 - 151 |
NISHIMURA H ET AL., SCIENCE, vol. 291, 2001, pages 319 - 322 |
OKAZAKI ET AL., CURR. OPIN. IMMUNOL., vol. 14, 2002, pages 391779 - 82 |
OKAZAKI ET AL., PNAS, vol. 98, 2001, pages 13866 - 71 |
OKAZAKI T ET AL., J. EXP MED., vol. 208, 2011, pages 395 - 407 |
PARDOLL DM., NAT REV CANCER, vol. 12, 2012, pages 252 - 264 |
PROKUNINA; ALARCON-RIQUELME, HUM MOL GENET, vol. 13, 2004, pages R143 |
ROSENBERG SA ET AL.: "Cancer immunotherapy in Cancer: Principles & Practice of Oncology", 2011, LIPPINCOTT WILLIAMS & WILKINS, pages: 332 - 344 |
S.-R. WOO ET AL: "Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape", CANCER RESEARCH, vol. 72, no. 4, 20 December 2011 (2011-12-20), pages 917 - 927, XP055151722, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-11-1620 * |
SALAMA ET AL., J EXP MED, vol. 198, 2003, pages 71 - 78 |
SCHLICH E ET AL., ERNAHRUN S UMSCHAU, vol. 57, 2010, pages 178 - 183 |
TERME M ET AL., CANCER RES, vol. 71, 2011, pages 5393 - 5399 |
THOMAS, M.L., JEXP MED, vol. 181, 1995, pages 1953 - 6 |
TOPALIAN SL ET AL., NEJM, vol. 366, no. 26, 2012, pages 2443 - 2454 |
TRIEBEL F ET AL., J. EXP. MED., vol. 171, 1990, pages 1393 - 1405 |
TURNIS M E ET AL: "Combinatorial immunotherapy: PD-1 may not be LAG-ing behind any more", ONCOIMMUNOLOGY, vol. 1, no. 7, 2012, LANDES BIOSCIENCE USA, pages 1172 - 1174, XP002734390, ISSN: 2162-4011 * |
VERBRAECKEN, J. ET AL., METABOLISM - CLINICAL AND EXPERIMENTAL, vol. 55, no. 4, April 2006 (2006-04-01), pages 515 - 24 |
VIVIER, E; DAERON, M, IMMUNOL TODAY, vol. 18, 1997, pages 286 - 91 |
WOLCHOK ET AL., NEJM, vol. 369, no. 2, 2013, pages 122 - 33 |
WOLCHOK JD ET AL., CLIN. CAN. RES., vol. 15, no. 23, 2009, pages 7412 - 7420 |
WOO SR ET AL., CANCER RES., vol. 72, 2012, pages 917 - 927 |
WORKMAN CJ ET AL., J. IMMUNOL., vol. 174, 2005, pages 688 - 695 |
WORKMAN CJ ET AL., J. IMMUNOL., vol. 182, no. 4, 2009, pages 1885 - 91 |
Cited By (202)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10906975B2 (en) | 2012-02-15 | 2021-02-02 | Novo Nordisk A/S | Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
US10189904B2 (en) | 2012-02-15 | 2019-01-29 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
US10377824B2 (en) | 2012-07-02 | 2019-08-13 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof |
US9505839B2 (en) | 2012-07-02 | 2016-11-29 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof |
US11345752B2 (en) | 2012-07-02 | 2022-05-31 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof |
US10266591B2 (en) | 2012-07-02 | 2019-04-23 | Bristol-Myers Squibb Company | Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof |
US10081681B2 (en) | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
US11274152B2 (en) | 2013-09-20 | 2022-03-15 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
US11708412B2 (en) | 2013-09-26 | 2023-07-25 | Novartis Ag | Methods for treating hematologic cancers |
US11365255B2 (en) | 2013-12-12 | 2022-06-21 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
US10344090B2 (en) | 2013-12-12 | 2019-07-09 | Shanghai Hangrui Pharmaceutical Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
US10736940B2 (en) | 2013-12-19 | 2020-08-11 | Immutep S.A.S. | Combined preparations for the treatment of cancer |
US11117970B2 (en) | 2014-01-23 | 2021-09-14 | Regeneron Pharmaceuticals, Inc. | Human antibodies to PD-L1 |
US9938345B2 (en) | 2014-01-23 | 2018-04-10 | Regeneron Pharmaceuticals, Inc. | Human antibodies to PD-L1 |
US10737113B2 (en) | 2014-01-23 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Human antibodies to PD-1 |
US9987500B2 (en) | 2014-01-23 | 2018-06-05 | Regeneron Pharmaceuticals, Inc. | Human antibodies to PD-1 |
US9815898B2 (en) | 2014-01-24 | 2017-11-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
US11827704B2 (en) | 2014-01-24 | 2023-11-28 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
US9683048B2 (en) | 2014-01-24 | 2017-06-20 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
US10752687B2 (en) | 2014-01-24 | 2020-08-25 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
EP3988572A1 (en) * | 2014-01-28 | 2022-04-27 | Bristol-Myers Squibb Company | Anti-lag-3 antibodies to treat hematological malignancies |
EP3556775A1 (en) * | 2014-01-28 | 2019-10-23 | Bristol-Myers Squibb Company | Anti-lag-3 antibodies to treat hematological malignancies |
WO2015116539A1 (en) * | 2014-01-28 | 2015-08-06 | Bristol-Myers Squibb Company | Anti-lag-3 antibodies to treat hematological malignancies |
US10472419B2 (en) | 2014-01-31 | 2019-11-12 | Novartis Ag | Antibody molecules to TIM-3 and uses thereof |
US11155620B2 (en) | 2014-01-31 | 2021-10-26 | Novartis Ag | Method of detecting TIM-3 using antibody molecules to TIM-3 |
US10981990B2 (en) | 2014-01-31 | 2021-04-20 | Novartis Ag | Antibody molecules to TIM-3 and uses thereof |
US9908936B2 (en) | 2014-03-14 | 2018-03-06 | Novartis Ag | Antibody molecules to LAG-3 and uses thereof |
US11098119B2 (en) | 2014-06-26 | 2021-08-24 | Macrogenics, Inc. | Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof |
US10160806B2 (en) | 2014-06-26 | 2018-12-25 | Macrogenics, Inc. | Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof |
US11072654B2 (en) | 2014-07-17 | 2021-07-27 | Novo Nordisk A/S | Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity |
US11278620B2 (en) | 2014-08-19 | 2022-03-22 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
US10898571B2 (en) | 2014-08-19 | 2021-01-26 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
US10188730B2 (en) | 2014-08-19 | 2019-01-29 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
US11207406B2 (en) | 2014-08-19 | 2021-12-28 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
US11344620B2 (en) | 2014-09-13 | 2022-05-31 | Novartis Ag | Combination therapies |
US11352440B2 (en) | 2014-11-21 | 2022-06-07 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
US10940181B2 (en) | 2015-01-09 | 2021-03-09 | Immutep S.A.S. | Combined preparations for the treatment of cancer or infection |
US11684654B2 (en) | 2015-01-09 | 2023-06-27 | Immutep S.A.S. | Combined preparations for the treatment of cancer or infection |
US10874713B2 (en) | 2015-01-09 | 2020-12-29 | Immutep S.A.S. | Combined preparations for the treatment of cancer or infection |
WO2016110593A1 (en) * | 2015-01-09 | 2016-07-14 | Immutep S.A.S. | Combined preparations for the treatment of cancer or infection |
US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
US10512689B2 (en) | 2015-04-17 | 2019-12-24 | Bristol-Myers Squibb Company | Compositions comprising a combination of nivolumab and ipilimumab |
US11612654B2 (en) | 2015-04-17 | 2023-03-28 | Bristol-Myers Squibb Company | Combination therapy comprising nivolumab and ipilimumab |
EP3738610A1 (en) | 2015-04-17 | 2020-11-18 | Bristol-Myers Squibb Company | Compositions comprising a combination of ipilimumab and nivolumab |
EP3288980B1 (en) | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
US10174113B2 (en) | 2015-04-28 | 2019-01-08 | Bristol-Myers Squibb Company | Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody |
US12084518B2 (en) | 2015-05-21 | 2024-09-10 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
US11078278B2 (en) | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
EP3736290A1 (en) | 2015-05-29 | 2020-11-11 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
US10144779B2 (en) | 2015-05-29 | 2018-12-04 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
US10479833B2 (en) | 2015-05-29 | 2019-11-19 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
US11267889B2 (en) | 2015-05-29 | 2022-03-08 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
US11858991B2 (en) | 2015-06-08 | 2024-01-02 | Macrogenics, Inc. | LAG-3-binding molecules and methods of use thereof |
US11072653B2 (en) | 2015-06-08 | 2021-07-27 | Macrogenics, Inc. | LAG-3-binding molecules and methods of use thereof |
EP3868406A1 (en) | 2015-06-24 | 2021-08-25 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
WO2016207646A1 (en) | 2015-06-24 | 2016-12-29 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
EP3322731B1 (en) | 2015-07-14 | 2021-01-13 | Bristol-Myers Squibb Company | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) |
CN108348601B (en) * | 2015-07-22 | 2022-05-17 | 索伦托药业有限公司 | Antibody therapeutics that bind to LAG3 |
CN108348601A (en) * | 2015-07-22 | 2018-07-31 | 索伦托治疗有限公司 | The Antybody therapy agent combined with LAG3 |
CN114853891A (en) * | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | Antibody therapeutics that bind to LAG3 |
EP3325009A4 (en) * | 2015-07-22 | 2018-12-05 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind lag3 |
CN108136003A (en) * | 2015-07-29 | 2018-06-08 | 诺华股份有限公司 | The use in conjunction of anti-PD-1 and anti-M-CSF antibody in treatment of cancer |
US11623959B2 (en) | 2015-07-30 | 2023-04-11 | Macrogenics, Inc. | PD-1-binding molecules and methods of use thereof |
US10577422B2 (en) | 2015-07-30 | 2020-03-03 | Macrogenics, Inc. | PD-1-binding molecules and methods of use thereof |
WO2017025498A1 (en) * | 2015-08-07 | 2017-02-16 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
CN107922470A (en) * | 2015-08-07 | 2018-04-17 | 皮里斯制药有限公司 | To 1 specific novel fusion polypeptide of LAG 3 and PD |
US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
US11692032B2 (en) | 2015-10-09 | 2023-07-04 | Regeneron Pharmaceuticals, Inc. | Anti-LAG3 antibodies and uses thereof |
US10358495B2 (en) | 2015-10-09 | 2019-07-23 | Regeneron Pharmaceuticals, Inc. | Anti-LAG3 antibodies and uses thereof |
JP7184866B2 (en) | 2015-11-18 | 2022-12-06 | メルク・シャープ・アンド・ドーム・エルエルシー | PD1 and/or LAG3 binding substances |
US11168135B2 (en) | 2015-11-18 | 2021-11-09 | Merck Sharp & Dohme Corp. | PD1 and/or LAG3 binders |
US11155619B2 (en) | 2015-11-18 | 2021-10-26 | Merck Sharp & Dohme Corp. | PD1 and/or LAG3 binders |
WO2017087589A3 (en) * | 2015-11-18 | 2017-07-13 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
US10323090B2 (en) | 2015-11-18 | 2019-06-18 | Merck Sharp & Dohme Corp. | PD1 and/or LAG3 binders |
JP2021058197A (en) * | 2015-11-18 | 2021-04-15 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
US11168136B2 (en) | 2015-11-18 | 2021-11-09 | Merck Sharp & Dohme Corp. | PD1 and/or LAG3 binders |
US11840571B2 (en) | 2015-12-14 | 2023-12-12 | Macrogenics, Inc. | Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4 |
US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
JP7000322B2 (en) | 2015-12-16 | 2022-02-04 | メルク・シャープ・アンド・ドーム・コーポレーション | Anti-LAG3 antibody and antigen-binding fragment |
US11045547B2 (en) | 2015-12-16 | 2021-06-29 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
WO2017106129A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
EP3399989A4 (en) * | 2015-12-16 | 2019-08-07 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
JP2019503674A (en) * | 2015-12-16 | 2019-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Anti-LAG3 antibody and antigen-binding fragment |
US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
US10668152B2 (en) | 2015-12-17 | 2020-06-02 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
US11965031B2 (en) | 2015-12-17 | 2024-04-23 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
US12054557B2 (en) | 2015-12-22 | 2024-08-06 | Regeneron Pharmaceuticals, Inc. | Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer |
WO2017149143A1 (en) | 2016-03-04 | 2017-09-08 | Agency For Science, Technology And Research | Anti-lag-3 antibodies |
JP2019514844A (en) * | 2016-03-04 | 2019-06-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Combination therapy with anti-CD73 antibody |
WO2017194265A1 (en) | 2016-05-10 | 2017-11-16 | Agency For Science, Technology And Research | Anti-CTLA-4 Antibodies |
US11505600B2 (en) | 2016-05-13 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods of treating skin cancer by administering a PD-1 inhibitor |
US10457725B2 (en) | 2016-05-13 | 2019-10-29 | Regeneron Pharmaceuticals, Inc. | Methods of treating skin cancer by administering a PD-1 inhibitor |
JP2019050804A (en) * | 2016-05-18 | 2019-04-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anti-pd1 and anti-lag3 antibodies for cancer treatment |
JP2019522460A (en) * | 2016-05-18 | 2019-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Anti-PD1 and anti-LAG3 antibodies for the treatment of cancer |
US11028169B2 (en) | 2016-05-18 | 2021-06-08 | Boehringer Ingelheim International Gmbh | Antibody molecules for cancer treatment |
US11795219B2 (en) | 2016-05-18 | 2023-10-24 | Boehringer Ingelheim International Gmbh | Antibody molecules for cancer treatment |
WO2017201502A1 (en) | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
WO2017220988A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
US11981733B2 (en) | 2016-06-23 | 2024-05-14 | Jiangsu Hengrui Medicine Co., Ltd. | LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof |
TWI757304B (en) * | 2016-06-23 | 2022-03-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | Lag-3 antibody, antigen-binding fragments and pharmaceutical use thereof |
WO2017219995A1 (en) * | 2016-06-23 | 2017-12-28 | 江苏恒瑞医药股份有限公司 | Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof |
US11155617B2 (en) | 2016-06-23 | 2021-10-26 | Jiangsu Hengrui Medicine Co., Ltd. | LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof |
CN109414490A (en) * | 2016-07-01 | 2019-03-01 | 小利兰·斯坦福大学理事会 | Inhibition immunity receptor suppressing method and composition |
WO2018006066A1 (en) * | 2016-07-01 | 2018-01-04 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitory immune receptor inhibition methods and compositions |
US11834503B2 (en) | 2016-10-13 | 2023-12-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anti-lag-3 antibodies and compositions |
US11359018B2 (en) | 2016-11-18 | 2022-06-14 | Symphogen A/S | Anti-PD-1 antibodies and compositions |
WO2018106862A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
EP4289484A2 (en) | 2016-12-07 | 2023-12-13 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
US10912831B1 (en) | 2016-12-07 | 2021-02-09 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
US11013802B2 (en) | 2016-12-07 | 2021-05-25 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
US11638755B2 (en) | 2016-12-07 | 2023-05-02 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
US10905784B2 (en) | 2017-02-10 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-LAG3 antibodies for immuno-PET imaging |
US11511001B2 (en) | 2017-02-10 | 2022-11-29 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-LAG3 antibodies for immuno-PET imaging |
US11858994B2 (en) | 2017-03-15 | 2024-01-02 | Repertoire Genesis Incorporation | Biomarkers for cancer immunotherapy |
WO2018183928A1 (en) | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
EP4368200A2 (en) | 2017-04-05 | 2024-05-15 | Boehringer Ingelheim International GmbH | Anticancer combination therapy |
RU2795232C2 (en) * | 2017-04-05 | 2023-05-02 | Симфоген А/С | Combined medicinal products targeting pd-1, tim-3 and lag-3 |
JP7523491B2 (en) | 2017-04-05 | 2024-07-26 | チア・タイ・ティエンチン・ファーマシューティカル・グループ・カンパニー・リミテッド | Combination therapy targeting PD-1, TIM-3, and LAG-3 |
WO2018185135A1 (en) | 2017-04-05 | 2018-10-11 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
EP4116328A1 (en) * | 2017-04-05 | 2023-01-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combination therapies targeting pd-1, tim-3, and lag-3 |
JP2022133296A (en) * | 2017-04-05 | 2022-09-13 | シムフォゲン・アクティーゼルスカブ | Combination therapies targeting pd-1, tim-3, and lag-3 |
WO2018185232A1 (en) * | 2017-04-05 | 2018-10-11 | Symphogen A/S | Combination therapies targeting pd-1, tim-3, and lag-3 |
JP2020513009A (en) * | 2017-04-05 | 2020-04-30 | シムフォゲン・アクティーゼルスカブSymphogen A/S | Combination therapy targeting PD-1, TIM-3, and LAG-3 |
TWI822101B (en) * | 2017-04-05 | 2023-11-11 | 大陸商正大天晴藥業集團股份有限公司 | Combination therapies targeting pd-1, tim-3, and lag-3 |
TWI801376B (en) * | 2017-04-05 | 2023-05-11 | 法商施維雅藥廠 | Combination therapies targeting pd-1, tim-3, and lag-3 |
US11939380B2 (en) | 2017-04-05 | 2024-03-26 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
US11607453B2 (en) | 2017-05-12 | 2023-03-21 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
WO2018217940A3 (en) * | 2017-05-24 | 2019-06-13 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
WO2018217944A1 (en) * | 2017-05-24 | 2018-11-29 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
WO2018222722A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
US11807686B2 (en) | 2017-05-30 | 2023-11-07 | Bristol-Myers Squibb Company | Treatment of LAG-3 positive tumors |
EP3631454B1 (en) * | 2017-05-30 | 2023-09-13 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
US11723975B2 (en) | 2017-05-30 | 2023-08-15 | Bristol-Myers Squibb Company | Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody |
US12049503B2 (en) | 2017-05-30 | 2024-07-30 | Bristol-Myers Squibb Company | Treatment of LAG-3 positive tumors |
WO2018226336A1 (en) | 2017-06-09 | 2018-12-13 | Providence Health & Services - Oregon | Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer |
US11938192B2 (en) | 2017-06-14 | 2024-03-26 | Medimmune Limited | Dosage regimes for the administration of an anti-CD19 ADC |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
US11390679B2 (en) | 2017-08-30 | 2022-07-19 | Phanes Therapeutics, Inc. | Anti-LAG-3 antibodies and uses thereof |
US11976125B2 (en) | 2017-10-13 | 2024-05-07 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
US11919957B2 (en) | 2017-10-15 | 2024-03-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | Methods of treating tumor |
US11732044B2 (en) | 2017-12-27 | 2023-08-22 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-LAG-3 antibody and use thereof |
WO2019129137A1 (en) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anti-lag-3 antibody and uses thereof |
US11655295B2 (en) | 2018-01-18 | 2023-05-23 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-LAG-3 antibody and use thereof |
CN112236456B (en) * | 2018-03-20 | 2023-12-22 | 上海药明生物技术有限公司 | Novel bispecific PD-1/LAG-3 antibody molecules |
WO2019179422A1 (en) * | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/lag-3 antibody molecules |
CN112236456A (en) * | 2018-03-20 | 2021-01-15 | 上海药明生物技术有限公司 | Novel bispecific PD-1/LAG-3 antibody molecules |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
WO2019191676A1 (en) | 2018-03-30 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2019224275A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
WO2019241098A1 (en) * | 2018-06-11 | 2019-12-19 | Yale University | Novel immune checkpoint inhibitors |
EP3802922B1 (en) | 2018-06-11 | 2023-04-26 | Yale University | Novel immune checkpoint inhibitors |
WO2020002905A1 (en) | 2018-06-25 | 2020-01-02 | Immodulon Therapeutics Limited | Cancer therapy |
US11945864B2 (en) | 2018-06-29 | 2024-04-02 | Y-Biologics Inc. | Monoclonal antibody specifically binding to LAG-3 and use thereof |
EP3816187A4 (en) * | 2018-06-29 | 2022-08-03 | Y-Biologics Inc. | Monoclonal antibody specifically binding to lag-3 and use thereof |
US11807692B2 (en) | 2018-09-25 | 2023-11-07 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
US20210338813A1 (en) * | 2018-10-19 | 2021-11-04 | Bristol-Myers Squibb Company | Combination Therapy for Melanoma |
WO2020081928A1 (en) * | 2018-10-19 | 2020-04-23 | Bristol-Myers Squibb Company | Combination therapy for melanoma |
WO2020232019A1 (en) * | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
WO2021025177A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
WO2021055994A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
WO2021092380A1 (en) | 2019-11-08 | 2021-05-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
WO2021104834A1 (en) | 2019-11-27 | 2021-06-03 | Adc Therapeutics Sa | Combination therapy |
WO2021147837A1 (en) | 2020-01-21 | 2021-07-29 | 上海复宏汉霖生物技术股份有限公司 | Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof |
EP4161964A4 (en) * | 2020-06-05 | 2024-02-07 | Beijing Mabworks Biotech Co., Ltd | Antibodies binding lag3 and uses thereof |
WO2022008519A1 (en) | 2020-07-07 | 2022-01-13 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
WO2022047189A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
WO2022136255A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022136266A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022136257A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
WO2022146947A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022261018A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023061930A1 (en) | 2021-10-11 | 2023-04-20 | BioNTech SE | Therapeutic rna for lung cancer |
WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
WO2024137776A1 (en) | 2022-12-21 | 2024-06-27 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
WO2024175699A1 (en) * | 2023-02-23 | 2024-08-29 | Imcheck Therapeutics | Combination of btn3a activating antibody and immune checkpoint inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11274152B2 (en) | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors | |
US20240150459A1 (en) | Anti-LAG-3 Antibodies to Treat Hematological Malignancies | |
BR122024007073A2 (en) | COMPOSITION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14786389 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/003103 Country of ref document: MX |
|
REEP | Request for entry into the european phase |
Ref document number: 2014786389 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 244547 Country of ref document: IL Ref document number: 15021102 Country of ref document: US Ref document number: 2014786389 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2924524 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016515520 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016005816 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014323523 Country of ref document: AU Date of ref document: 20140918 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167009856 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201690617 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 112016005816 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160317 |